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ABSTRACT 
Hepatitis C virus (HCV) is the causative agent of Hepatitis C, a serious global health 
problem which results in liver cirrhosis and hepatocellular carcinoma. Currently there is no 
effective treatment or vaccine against the virus. Therefore, development of a therapeutic vaccine 
is of paramount importance. In this project, three alternative approaches were used to control 
HCV including a DNA vaccine, a recombinant viral vaccine and RNA interference.  
The first approach was to test the effect of different promoters on the efficacy of a DNA 
vaccine against HCV. Plasmids encoding HCV-NS3 and E1 antigens were designed under three 
different promoters, adenoviral E1A, MLP, and CMV ie. The promoter effect on the antigen 
expression in 293 cells, as well as on the antibody level in immunized BALB/c mice, was 
evaluated. The results showed that the antigens were successfully expressed from all vectors. The 
CMV ie promoter induced the highest antigen expression and the highest antibody level.  
Second, the efficiency of a recombinant adenovirus vaccine encoding HCV-NS3 was 
compared to that of a HCV-NS3 plasmid vaccine. The results showed that the recombinant 
adenovirus vaccine induced higher antibody levels as compared to the plasmid vaccine.  
The relationship between the immune response and miRNA was also evaluated. The 
levels of mir-181, mir-155, mir-21 and mir-296 were quantified in the sera of immunized 
animals. mir-181 and mir-21 were found to be upregulated in animals injected with adenoviral 
vectors.  
Third, two recombinant adenoviruses encoding siRNAs targeting both the helicase and 
protease parts of the NS3 region were tested for their ability to inhibit NS3 expression. The 
results showed that the siRNA against protease was more effective in silencing the HCV-NS3 
gene in a HCV replicon cell line. This result confirmed the efficiency of adenovirus for siRNA 
delivery. 
These results confirmed that CMV ie is optimum promoter for immune response 
induction. Adenovirus was shown to be an effective delivery vector for antigens or siRNAs. In 
addition, miRNAs were proved to be involved in the regulation of immune response.  
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PROJECT OVERVIEW 
1- Background 
Hepatitis C virus (HCV) constitutes a major global concern that affects more than 
170 million individuals worldwide.  Chronic HCV infection usually progresses to liver 
cirrhosis and hepatocellular cancer, resulting in a high annual mortality rate (Saito et al., 
1990).  Currently, there is no effective treatment or vaccine against the virus. This is due 
in large part to the high mutation rate of HCV, enabling the virus to escape the body’s 
natural immune responses, as well as immunity acquired by vaccinations. The genomic 
mutations also contribute to the virus’s ability to resist therapy.  Therefore, development 
of an effective therapeutic vaccine is of paramount importance both for the prevention 
and treatment of HCV.  
In order for a vaccine to be effective in preventing chronic HCV infection, it must 
trigger an early, strong immune response.  Efficient antigen expression and delivery are 
important for the induction of a potent immune response.  Although traditional vaccines 
based on inactivated or attenuated infectious agents are often effective, they run the risk 
of retrieving the wild type virus. This risk increases when the mutation rate is high, as is 
the case for HCV.  This has led to the development of novel vaccine approaches.  During 
the last two decades, DNA-based vaccination has gained attention due to its ability to 
produce both humoral and cellular immune responses, as well as its ease of use, safety, 
and low cost of preparation. However, this approach still requires optimization to be of 
clinical use.  Since antigen expression levels and delivery are two key factors that induce 
a potent immune response, recombinant viral vaccines, that exhibit enhanced cellular 
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uptake efficiency, provide another attractive alternative. Finally, new therapeutic 
approaches including siRNA are being developed that depend on the inhibition of viral 
replication by silencing their vital enzymes.  In this thesis, these three current approaches 
are explored, evaluated, and compared in order to determine which approach might best 
be employed to develop an effective vaccine or therapy against HCV.  
2- Overall objective 
 The primary goal of this project is to study strategies for prevention and treatment 
of HCV. To achieve this goal, three distinct but complementary approaches were used:  
(1) a plasmid DNA vaccine with different promoters, (2) a recombinant adenoviral vector 
vaccine, and (3) a small interfering RNA (siRNA) based strategy. 
3- Experimental design 
The first two approaches developed in this study are HCV vaccines involving the 
following steps:  (1) identify the antigens of interest, (2) engineer a construct consisting 
of the gene of interest under the control of an appropriate promoter, (3) insert the 
construct into the vehicle of choice (e.g., plasmid or  adenoviral vector) for delivery to 
the host cell, (4) test the construct for efficacy in cell culture, (5) test the construct for 
immune response in vivo using a small animal model (e.g., mouse), and (6) evaluate and 
compare the results to optimize the efficacy of the potential HCV vaccine.  The third 
approach used in this study is an evaluation of an HCV vaccine/therapy that combines the 
adenoviral vector delivery system with siRNA as a means to target and inactivate the 
critical viral enzymes, helicase and protease.  
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4- Chapter overviews 
 In Chapter 1, a literature review is conducted describing the HCV life cycle, 
pathogenesis, biology, and treatments. The human immune response to infection is also 
discussed.  Current approaches in vaccine development are highlighted. Methods aimed 
at eliciting and enhancing the immunological response to HCV infection are introduced, 
and additional strategies to target and clear the virus are discussed. 
 Chapter 2 describes the development of plasmid DNA vaccines using two 
specific HCV antigens:  NS3 and E1.  In order to optimize the antigen expression levels 
for NS3 and E1, the effect of promoter strength on vaccine efficacy was tested and 
evaluated using three promoters:  (1) cytomegalovirus immediate early promoter (CMV 
ie), (2) adenoviral early E1A promoter (E1Ap), and (3) adenoviral major late promoter 
(MLP). Promoter strength was measured by transcription levels and antibody production 
in cell culture and mouse models respectively. In addition, changes in mouse miRNA 
serum levels after immunization were evaluated for three miRNAs known to be involved 
in the immune response:  (1) miRNA-21, (2) miRNA-181, and (3) miRNA-296. 
Promising directions for further vaccine development are also discussed. 
 Chapter 3 describes the construction of a recombinant adenoviral vector vaccine 
against HCV NS3 (rAdNS3) under the control of the CMV ie promoter.  Construct 
efficacy, measured as antigen transcription efficiency, is evaluated in cell culture (HeLa 
cells) and antibody production was evaluated in mice. Mouse serum miRNA -21, -181, 
and -296 levels are also measured and the results are compared to those observed for the 
plasmid DNA vaccine developed in chapter 2. 
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In Chapter 4, an alternative strategy was utilized to evaluate the efficacy of RNA 
interference (RNAi) against HCV-NS3 as a therapeutic tool.  Two short hairpin RNAs 
(shRNA) expressed by adenovirus were constructed to target the HCV-NS3 region, 
which encodes two enzymes that are critical to HCV replication:  protease and helicase.  
The constructs were tested in the animal model system, to test infecting hepatoma cells 
expressing the HCV 1b genome (Con1-FL/Neo) with each AdshRNA.  NS3 RNA was 
quantified using qRT-PCR and the results are discussed.  
Finally a general conclusion of the overall results and trends that emerge from this 
thesis is provided. The potential applications of the thesis, the next steps to be taken in 
vaccine development, and directions for future research are outlined. 
5- Key findings 
Four key findings emerge from this thesis. First, the CMV ie promoter had the 
highest level of expression for E1 and NS3 genes, making CMV ie the promoter of 
choice.  Second, all vaccines elicited a specific antibody response and the recombinant 
adenoviral vector vaccine expressing NS3 induced a higher immune response than the 
DNA vaccine. Third, certain miRNAs were upregulated in animals injected with 
adenoviral vectors compared to plasmid DNA vaccines, providing additional support for 
the efficacy of the viral vector vaccine. This finding also points to these miRNAs as 
potential indicators of immune response activation. Fourth, siRNA against HCV protease 
was effective in silencing the HCV-NS3 gene. This suggests that these approaches are 
promising for both prevention and treatment of HCV, and warrant further investigation. 
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Chapter 1: LITERATURE REVIEW 
1.1- Introduction 
 HCV is a major health concern that leads to liver failure affecting more than 170 
million people, representing around 3% of the world's population (Wasley and Alter, 
2000). The virus is the causative agent of hepatitis C, a liver-associated disease.  HCV is 
transmitted by blood and to a lesser extent through sexual and maternal routes. Although 
other hepatitis viruses exist, vaccines are available for both hepatitis A and hepatitis B 
but not for HCV, making the latter the leading cause for liver disease-associated death 
and the primary reason for liver transplantation.  HCV infection has spread in developing 
countries due to unsafe medical practices.  Although infection through blood transfusion 
has decreased significantly in developed countries since 1992 when blood screening for 
HCV became available, the prevalence of the infection remains high as those previously 
infected only start to show serious symptoms years after infection. The prevalence of 
infection is also elevated in high risk groups including intravenous drug users and HIV 
patients. Coinfection with HIV and HCV accelerates the progression to liver cirrhosis and 
failure (Weber et al., 2006).  Since no effective vaccine is available, the virus remains a 
serious global health threat.  Even with the available therapy based on a combination of 
IFN and ribavirin, complete resolution of the virus is not achieved in most infected 
patients.  Thus, novel therapeutic approaches are being investigated, such as inhibitors 
and RNAi against viral enzymes.  Moreover, there is currently no vaccine against HCV 
due in part to the heterogeneity of the virus.  Extensive research focuses on developing 
vaccines against the virus and some vaccines have been evaluated in clinical trials.  In the 
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sections that follow, a literature review highlighting current knowledge in the field will 
be provided.  First, the biology and immunology of HCV and progress in virus control 
will be discussed.  Second, different vaccine and therapeutic approaches against HCV 
will be introduced. 
1.2- Hepatitis C virus discovery 
HCV was first discovered in the seventies in post transfusion hepatitis cases. The 
new agent at the time was clinically and histologically similar to the two known hepatitis 
viruses, A and B, but lacked the serological markers of the latter viruses.  Therefore, the 
yet unknown agent was referred to as non-A, non-B (NANB) Hepatitis (Feinstone et al., 
1975). In the late 80s the genome of the infectious agent was isolated and cloned, and the 
virus was identified as HCV (Choo et al., 1989). Based on the structural and virological 
characteristics, HCV was classified in the Flaviviridae family, which is divided into three 
genera: flavivirus, pestivirus, and hepacivirus (Rosenberg, 2001). The Hepacivirus genus 
includes HCV and another two members, tamarin virus and GB virus B (Lindenbach and 
Rice, 2001).  
1.3- Hepatitis C Virus pathogenesis 
HCV infects hepatocytes and is transmitted mainly by blood contact. To date, 
there are more than 170 million people chronically infected with HCV throughout the 
world. Only 15% of infected people develop a strong immune response capable of 
eliminating the infection during the acute phase, which lasts for about 6 months while 
more than 85% enter the chronic phase, during which the virus persists and replicates in 
the liver. The infection remains asymptomatic for around 20-30 years before it progresses 
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to liver cirrhosis, liver failure, or hepatocellular carcinoma (Alter, 1995; Levrero, 2006). 
The asymptomatic nature of the infection contributes to the increasing spread of the virus, 
as infected people may not be aware of their infection until a later stage.  
 
1.4- Hepatitis C virus structure and genome 
HCV is a small, spherical, enveloped virus of 55-65 nm in diameter (Kaito et al., 1994). 
Under the envelope, a protein capsid surrounds the positive single-stranded RNA 
genome. Glycoproteins are embedded in the outer envelope. HCV structure is illustrated 
in Figure 1.1. The HCV genome consists of a long open reading frame (ORF) of ~9600 
nucleotides (nt). The coding region is flanked by the 5’ and 3’ untranslated regions 
(UTR). The 5’UTR is a highly conserved region of approximately 340 nt. It has a strong 
secondary structure and contains the internal ribosomal entry site (IRES) that mediates 
ribosome binding, and translation initiation (Pilipenko et al., 1989). The 3’UTR is a less 
conserved and less structured region of about 200 nt. It contains a poly-uridyl tract, with 
various lengths in different strains, which was found to be essential for viral RNA 
replication (Friebe and Bartenschlager, 2002; Yi and Lemon, 2003a; 2003b). The genome 
is translated into a single polyprotein precursor of ~3000 amino acids, which is co- and 
post-translationally processed by cellular peptidases and viral proteases to produce three 
structural and six non-structural viral proteins in addition to the p7 protein (reviewed in 
Penin et al., 2004). The structural proteins are cleaved with cellular peptidases, releasing 
the core protein which forms the nucleocapsid surrounding the viral genome as well as 
the envelope glycoproteins 1 and 2 (E1 and E2) that are involved in the attachment and 
entry into the host cell. The nonstructural proteins, designated NS2, NS3, NS4A, NS4B, 
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NS5A, and NS5B are released by the viral proteases (Dubuisson et al., 2002). These 
proteins are involved in viral replication and host immune evasion (Lai, 2000).  
                                             
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Schematic diagram of the structure of HCV.  
 
1.5- Hepatitis C virus proteins 
The core protein is a highly conserved multifunctional protein. Aside from its 
structural function in forming the viral capsid, it is implicated in viral replication, 
maturation, and pathogenesis (Suzuki and Suzuki, 2006). E1 and E2 glycoproteins are 
involved in receptor binding and entry into the host cell. E1 and E2 form a non-covalent 
heterodimer which assists in viral attachment. E2 is the most variable region in the viral 
Lipid 
envelope 
Genomic   
RNA 
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polyprotein as it contains two hypervariable regions (HVR) (Op De Beeck et al., 2001; 
Cocquerel et al., 2002). P7 is a small hydrophobic protein forming an ion channel 
embedded in the endoplasmic reticulum (ER) membrane (Griffin et al., 2003; Pavlovic et 
al., 2003). P7 is essential for RNA replication, viral assembly, and release (Jones et al., 
2007; Steinmann et al., 2007). NS2 together with the N’ terminal domain of NS3 forms a 
zinc-stimulated autoprotease that cleaves the NS2/NS3 junction (Grakoui et al., 1993; 
Hijikata et al., 1993). NS3 is a large multifunctional protein with enzymatic activities that 
are essential for viral RNA replication and polyprotein processing. The N’ terminal 
portion of NS3 (180 amino acids) is a serine protease which works with cofactor NS4A 
to cleave the downstream junctions and release NS proteins. The rest of the protein 
comprises the helicase-NTPase domain, which unwinds RNA during replication 
(Kolykhalov et al., 2000; Lam and Frick, 2006). The function of NS4B is not clear, but it 
is thought to have a role in the formation of HCV membranous replication complexes 
(Egger et al., 2002; Gao et al., 2004). NS5A is a phosphoprotein which has a role in the 
regulation of RNA replication (Evans et al., 2004; Gao et al., 2004), as well as inhibition 
of the host immune response (Kriegs et al., 2009). NS5B is an RNA dependent RNA 
polymerase (RdRP). It is a highly conserved protein which initiates the synthesis of new 
RNA strands (Schmidt-Mende et al., 2001; Moradpour et al., 2004). NS5B lacks proof 
reading ability, thus it is prone to a high mutation rate. This contributes to the high 
genetic diversity of HCV, enabling the virus to escape the host immune response, often 
leading to treatment failure. Figure 1.2 shows the HCV genome and encoded proteins. 
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Figure 1.2: HCV genome structure and protein processing. (Moradpour et al.,  2007). 
 
1.6- Hepatitis C virus life cycle 
HCV replicates in the hepatocytes (Shimizu et al., 1990; Nouri-Aria et al., 1995). 
The HCV infection cycle consists of five steps: attachment and entry, protein translation 
and processing, genome replication, viral assembly and exit. The first step is attachment 
and entry into the host cell. Different cell surface molecules are thought to be involved in 
HCV attachment, and work together to facilitate viral entry into host cells. These 
receptors include: Cluster of Differentiation 81 (CD81) (Pileri et al., 1998), the human 
scavenger receptor class B type I (SR-BI) (Scarselli et al., 2002), the liver and lymph 
node-specific intercellular adhesion molecule-3-grabbing integrin (L-SIGN), the dendritic 
cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) 
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(Gardner et al., 2003; Lozach et al., 2003; Pohlmann et al., 2003) and a tight junction 
component claudin-1 (Evans et al., 2007). The viral proteins E1 and E2 bind to cellular 
complex receptors and the virus enters the cell by clathrin-mediated endocytosis 
(Bartosch et al., 2003; Nielsen et al., 2004). Following entry, the fusion of endosomal 
and viral membranes leads to the release of viral RNA into the cytoplasm (Moradpour et 
al., 2007).  
The positive sense viral RNA is immediately translated using the cellular 
machinery in a cap-independent manner, mediated by the IRES (Luo et al., 2003). 
Translation is initiated in the cytoplasm, where the polyprotein is processed, producing 
the individual proteins. The mature proteins localize to the ER where the NS proteins and 
viral RNA form the replication complex (Penin et al., 2004; Egger et al., 2002). 
Replication is performed by the viral RdRP, through a negative-strand RNA intermediate 
(Bartenschlager et al., 2004). The new RNA strands, with the structural protein, combine 
to form new viral particles which acquire an envelope by budding through the ER 
membranes. The viral particles are then released from the cell by exocytosis (Dash et al., 
1997; Mizuno et al., 1995). HCV is not a lytic virus, and does not lead to cell death. The 
life cycle of HCV is shown in Figure 1.3. 
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Figure 1.3: The life cycle of HCV (Pereira and Jacobson, 2009). 
 
1.7- Hepatitis C virus genotypes  
HCV has an extremely heterogeneous genome, due to rapid replication and the 
poor fidelity of its RNA polymerase. It goes through 1.5–2.0 x 10-3 nt  substitutions per 
site per year (Bukh et al., 1995). Based on its genetic variability, HCV is classified into 
six major genotypes designated 1 to 6, which further divide into multiple subtypes 
(Robertson et al., 1998; Simmonds, 1995). Furthermore, infected hosts may harbor 
multiple virus genotypes, which are referred to as a quasispecies (Domingo et al., 1985; 
Weiner et al., 1992; Wyatt et al., 1998). The various genotypes differ in their 
geographical distribution (Bukh et al., 1995). For instance, HCV genotype 1 is 
predominant in Europe and North America, while genotypes 2, 4 and 5 are found in 
Africa (Candotti et al., 2003; Verbeeck et al., 2006). Genotype 6 is the main strain found 
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in Asia. Egypt has the highest prevalence of HCV infection predominated by genotype 4. 
Almost 20% of the Egyptian population is infected with HCV (Ray, 2000; Frank et al., 
2000; Tanaka et al., 2004). This represents an increasing public health burden in Egypt 
(Deuffic-Burban et al., 2006). Moreover, the outcome of the alpha interferon (IFN-α) 
therapy greatly depends on the genotype, with genotypes 1 and 4 being the least 
responsive (Manns et al., 2001; Fried et al., 2002).  
 
1.8- The Interaction between HCV and host immunity 
1.8.1- The host immune response 
 The human immune system is effective at fighting infectious pathogens. The 
initial line of defense is the nonspecific innate immunity, which helps control the 
infection and activates the specific adaptive immunity, including the cellular and humoral 
immune response. HCV, like any virus, stimulates a series of antiviral pathways however, 
the persistence of the virus demonstrates its ability to evade the immune responses.   
 
1.8.1.1- Innate immunity 
The innate immune response is induced early after infection with HCV. The liver 
has different kinds of innate immune cells including Kuppfer cells (also known as resting 
macrophages), circulating natural killer (NK) cells and dendritic cells (DC). These cells, 
as well as hepatocytes, contain receptors that sense the viral infection through viral 
recognition patterns, such as the ssRNA and dsRNA produced during the viral replication 
cycle. These receptors belong to two families, the toll-like receptors (TLRs), which are 
trans-membrane receptors located in the endosome, and RIG-1 like receptors (RLRs) 
which are located in the cytoplasm. Activation of these receptors induces IFNs,                                                                                                                        
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key proteins involved in the early control of  viral infection (Kanto and Hayashi, 2007). 
IFNs use multiple redundant pathways to prevent viral spread to neighboring cells 
(Figure 1.4). This adaptation overcomes the viral defense mechanisms. IFNs activate 
transcription of several antiviral genes and play a role in the maturation of NK cells, other 
key players involved in the innate immune response (reviewed in Racanelli and 
Rehermann, 2006). 
 
1.8.1.1.1- Interferon induction pathways 
Viral dsRNA is detected by TLR-3, located in hepatocytes, DCs and 
macrophages, and initiates signal transduction through the adaptor protein TIR-domain-
containing adaptor-inducing IFN-β (TRIF). Stimulation of TLR3 in endosomes and on 
the cell surface (Eisenacher et al., 2007) recruits IκB kinase (IKK), TANK-binding 
kinase 1 (TBK1) and IKKi. These kinases, together with adaptor molecules TANK and 
NAP1, induce the phosphorylation and nuclear translocation of interferon regulatory 
factor- (IRF) 3 and 7. In the nucleus, phosphorylated IRF-3 and IRF-7 collaborate with 
transcription factor activator protein-1 (AP-1) and nuclear factor kappa B (NF-κB), to 
regulate the expression of IFN-β (Asselah and Marcellin, 2011). 
An alternative pathway is mediated by cytoplasmic RLR including retinoic acid-
inducible gene-I (RIG-1) and the homologous protein melanoma differentiation-
associated gene-5 (MDA-5). RIG-1 is triggered by a polyuridine sequence in the 3’ non 
coding region (3’-NCR) (Hornung et al., 2006; Kato et al., 2008) and MDA-5 is triggered 
by long dsRNA. These sensor proteins bind dsRNA using their C terminal helicase. 
Through their N terminal CARD domains, a downstream signaling cascade is activated 
via the mitochondrial adaptor molecule IPS-1 (IFN-β promoter stimulator-1, also known 
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as CARDIF, MAVS and VISA) (Kawai et al., 2005; Seth et al., 2005; Xu et al., 2005). 
IPS-1 activates both IRF-3 and IRF-7 resulting in their dimerization and translocation to 
the nucleus where they induce the transcription of IFN-α/β. 
IFN -α/β binds to a common receptor (IFNAR-1/2) expressed at the cell surface of 
target cells, leading to activation of the JAK/STAT pathway. The activation of the Signal 
Transducers and Activators of Transcription (STAT) protein is mediated by 
phosphorylation by the Janus-family tyrosine kinases Tyk2 and Jak1. STAT1 and STAT2 
combine with IRF-9 forming the Interferon-Stimulated Transcription gene Factor-3 
(ISGF3) complex. The ISGF3 complex binds to the cis-acting IFN-stimulated Response 
Element (ISRE) in the nucleus initiating transcription of several IFN-inducible genes. 
These genes include protein kinase R (PKR), and oligoadenylate synthetase 
(OAS)/RNaseL (Gale and Foy, 2005). RNaseL degrades the viral RNA inhibiting 
translation (Asselah et al., 2009; 2010). PKR is an integral component in the human 
innate immune response mechanism. PKR recognizes and is activated by long stretches 
of dsRNA (Samuel, 2001; Cole, 2007). Subsequently PKR phosphorylates eukaryotic 
initiation factor 2α (eIF2α), resulting in the shutdown of cellular translation, and 
inhibition of viral proliferation (Garcia et al., 2006). The IFN pathways are summarized 
in Figure 1.4. 
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Figure 1.4: Innate immunity against HCV and the IFN pathway. (Asselah et al., 2009). 
 
1.8.1.1.2- Natural killer cells 
NK cells, a heterogeneous sub-population of cytotoxic lymphocytes, represent a 
major component of the innate immune system. They control the infection at early stages 
with their non-specific cytotoxic activity (Cerwenka and Lanier, 2001; Waldhauer and 
Steinle, 2008).  
Infected cells secrete alerting cytokines, which include IFN, Interleukins (IL): IL-
12, IL-15, IL-18, IL-2, and CCL5. These cytokines activate NK cell-mediated apoptosis. 
NK cells recognize target cells opsonized with immunoglobulin (Ig) G complexes via 
their FCγ-III receptor (CD16) (Cooper et al., 2001). They also recognize danger signals, 
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such as cells expressing abnormal or reduced levels of major histocompatibility complex 
(MHC) class I molecules, or pathogen-derived proteins and/or stress-induced cellular 
proteins (Hamerman et al., 2005). Activated NK cells kill infected cells directly, using 
perforin, a cytolytic protein that produces pores in the infected cell membrane. These 
pores create a channel through which granzyme proteases pass and lyse the cell (Larkin et 
al., 2006). NK cells also secrete a variety of cytokines, including IFN-γ, tumor necrosis 
factor α (TNF-α) and IL-4, which inhibit viral replication (Wang et al., 2008). They also 
stimulate the maturation of DCs, and initiate adaptive immune responses (Ahmad and 
Alvarez, 2004; Bendelac et al., 2007; Lanier et al., 2008).  
NK cells are abundant in the liver, constituting about 30% of the intra-hepatic 
lymphocytes, compared to 5-10% in peripheral blood (Norris et al., 1998). During an 
acute HCV infection, NK and NKT cells are triggered by IFN α and β and play a critical 
role in HCV clearance (Khakoo et al., 2004; Pelletier et al., 2010).  
 
1.8.1.2-   Adaptive immunity 
1.8.1.2.1- Humoral immune response 
Humoral immunity is conferred by antibodies secreted from B-lymphocytes 
upon activation during an infection. Neutralizing antibodies perform a major role in the 
clearance of many viral infections.  HCV infection induces antibodies against all viral 
proteins. HCV-specific antibodies appear in serum about 6-7 weeks after the initial 
infection. The delayed antibody response contributes to the persistence of the virus (Alter 
et al., 1989; Rahman et al., 2004). The first antibodies to be detected are those which 
target NS3 and core viral proteins while antibodies against NS4 and envelop proteins E1 
and E2 appear later (Orland et al., 2001). E2 has been a main target for neutralizing 
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antibodies however these antibodies failed to prevent reinfection with the same or a 
heterologous strain due to the high heterogeneity of E2 (Farci et al., 1992; Lai et al., 
1994). Therefore, the significance of the role of antibodies in the establishment of 
protective immunity was questioned, given reports that viral clearance was detected in 
acute infections, even in the absence of humoral immunity (Bjoro et al., 1994).  
The development of HCV models that enable the study of viral neutralization 
provides insight into the role of HCV antibodies in viral clearance and their impact on 
infection outcome (Bartenschlager and Lohmann, 2001). This is demonstrated by the 
ability of Virus-like particles (VLP) carrying core, E1 and E2 proteins, to produce 
neutralizing antibodies capable of protection against HCV infection in mice (Lechmann 
et al., 2001). 
 
1.8.1.2.2- Cellular immune response 
Cellular immunity is critical for HCV clearance. HCV proteins produce an innate 
immune response, which stimulates DC maturation and antigen presentation to T 
lymphocyte cells. DCs present antigens in association with MHC I and II, which is 
recognized by CD8+ and CD4+ T lymphocytes, respectively. DCs also secret cytokines 
and activate the T cells (Gonzalo et al., 2001). Activation of T helper (Th) CD4+ cells 
leads to cytokine production which differentiates CD4+ cells to Th1 that activates the 
cytotoxic response, or Th2, which activates the humoral response. An early CD4+ 
response is critical to HCV infection control. The Th1 phenotype in particular plays an 
important role in HCV resolution. Th1 helps activate and maintain cytotoxic T 
lymphocyte (CTL) CD8+ cells. The latter mediates viral clearance either by killing the 
infected cells, or by producing antiviral cytokines such as IFN, or TNF-α, which inhibits 
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viral replication and protects neighboring cells from invasion (Cooper et al., 1999; 
Lechner et al., 2000; Woollard et al., 2003). Cellular immune responses target many 
HCV proteins including core, E2, NS3 and NS5 (Ferrari et al., 1994; Hoffmann et al., 
1995). Robust and sustained specific CD8+ and CD4+ T cells were detected in patients 
who could resolve the acute infection, whereas chronic infection was found to be 
correlated with delayed and stunted immune responses.  HCV specific T cells are 
detected 7-10 weeks after infection, when the viral load has already reached high levels 
(Thimme et al., 2001; 2002).  
 
1.8.2- HCV evasion of the host immune system 
Despite the efficiency of the immune system in controlling viral infections, HCV 
can persist in the infected liver leading to a chronic disease. Generally, a vigorous 
immune response leads to viral clearance, whereas weak, impaired immune responses 
lead to persistence of infection. Since the majority of people infected with HCV are not 
able to clear the infection, it is suggested that HCV must employ multiple efficient 
strategies to subvert the host immune response. 
 
1.8.2.1- HCV interference with host innate immunity  
Multiple mechanisms are involved in the evasion of the host innate defense 
system. Different viral proteins interfere with viral detection sensors and IFN induction 
pathways (Gale and Foy, 2005) (Figure 1.5). For instance, NS3/NS4 protease inactivates 
both RIG-1 and TLR-3 pathways by cleaving their adaptor molecules IPS-1 (Meylan et 
al., 2005) and TRIF (Breiman et al., 2005; Li et al., 2005). In addition, HCV NS3/4A 
protease blocks the accumulation and nuclear translocation of phosphorylated IRF-3 and 
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the consequent expression of type I IFNs and IFN-stimulated genes (ISGs) (Foy et al., 
2003). IFN transcription is also inhibited by the interaction of NS3 and TBK1, disrupting 
the association between TBK1 and IRF-3 (Otsuka et al., 2005).   
 The core protein blocks IFN signaling through the JAK/STAT pathway, by the 
induction of inhibitory molecules such as suppressor of cytokine signaling 3 (SOCS3) 
(Bode et al., 2003), and phosphatase 2A (Duong et al., 2004). These inhibitory molecules 
interfere with STAT-1 and the formation of the transcription complex, thereby inhibiting 
the production of ISGs.  
Furthermore, the functions of several ISGs are impaired by HCV proteins. For 
example, PKR is inhibited by IRES (Vyas et al., 2003), E2 protein (Taylor et al., 1999) 
and NS5A (Pflugheber et al., 2002). NS5A also inhibits the 2–5 OAS/RNaseL pathway 
(Taguchi et al., 2004) and induces IL-8, which counteracts the antiviral effects of IFN 
(Polyak et al., 2001a). Moreover, these proteins correlate with resistance to the current 
IFN-based therapy for HCV infection (Berg et al., 2000; Witherell et al., 2000). 
In addition, mutations in the ribonuclease (RNase) L recognition sites in the HCV 
genome of certain strains allow them to escape nucleolytic cleavage, and resist IFN 
activity (Han and Barton, 2002). 
 
 
 
35 
 
 
 
 
Figure 1.5: HCV evasion of the innate immune system and blockage of IFN pathways. 
(Sklan et al., 2009). 
 
 
HCV has also evolved strategies to evade the NK cell response. The envelope 
protein E2 has been shown to crosslink to the CD81 receptor, suggesting an inhibitory 
effect on the cytotoxicity and IFN-γ production by NK cells (Crotta et al., 2002; Tseng 
and Klimpel, 2002; Yoon et al., 2009). Chronically infected patients have depleted and 
dysfunctional NK cells (Golden-Mason and Rosen, 2006).The impaired NK cells produce 
inhibitory cytokines including IL-10 and transforming growth factor-β (TGF-β), which 
suppress the adaptive immune response (Jinushi et al., 2004; Meier et al., 2005). In 
addition, the virus renders the infected hepatocytes resistant to NK cell attacks by 
expressing inhibitory ligands (Herzer et al., 2003; Wen et al., 2008). 
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1.8.2.2. - HCV interference with host adaptive immunity  
HCV has evolved multiple mechanisms to suppress the host adaptive immune 
response. HCV infection targets T cells, inhibiting their maturation, and impairing their 
functions involved in viral clearance. DCs are also targets for HCV evasion (Hiasa et al., 
1998; Sarobe et al., 2002). HCV’s core protein binds to the gC1q receptor on DCs, 
reducing the production of IL-12. This shifts the differentiation of CD4+ cells towards the 
Th2 phenotype, which is less effective in controlling the infection (Eisen-Vandervelde et 
al., 2004; Waggoner et al., 2005). The bias in Th1 to Th2 balance is also achieved by 
mutation selection. A mutation in the NS3 epitope, which is known to induce Th1 
immunity, results in the inactivation of CD4+ (Wang and Eckels, 1999; Wang et al., 
2003). 
Chronic HCV infection inhibits the maturation of effector CD8+ T cells, 
suppresses their ability to produce IFN-γ, and their cytotoxic activity (Wedemeyer et al., 
2002; Penna et al., 2007). Two mechanisms are suggested to affect CD8+ cell function, 
either failure in primary activation or exhaustion of initially activated cells by the high 
viral load. One suggested mechanism for cell exhaustion is the upregulation of 
programmed death–1 (PD-1) receptors on T cells, which converts the activated cells to 
the exhausted phenotype, with an impaired ability to proliferate or release cytokines 
(Penna et al., 2007).  In addition, the CD4+ CD25+ regulatory T (Treg) cells increase in 
numbers in the liver during chronic HCV infection. Treg cells secrete IL-10, which 
inhibits the functions of antigen presenting cells (APCs), including antigen processing, 
MHC expression and IL-12 production. Treg cells also inhibit HCV-specific CD8+ 
37 
 
proliferation (Boettler et al., 2005; Bolacchi et al., 2006).  Figure 1.6 shows the 
interference of HCV with host adaptive immunity. 
 
 
 
 
 
 
 
 
 
 
Figure 1.6: The evasion of the adaptive immune system by HCV (Sklan et al., 2009). 
 
Finally, the accumulation of mutations in the HCV genome plays a major role in 
immune system evasion. Mutations in immunodominant specific epitopes facilitate viral 
escape, due to failure in recognition by specific T or B cells or the impairment of binding 
of the epitope to the MHC on APCs (Bowen and Walker, 2005). Although the antibodies 
against the envelope proteins are more critical in viral neutralization, the high mutation 
rate in the HVRs of the E2 protein impairs the recognition of the neutralizing antibodies. 
Moreover, the heavy glycosylation of E2 suppresses the neutralizing effect of the 
antibodies (Farci et al., 2000).  
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1.9- HCV Treatment  
1.9.1- IFN-Ribavirin 
The sequence diversity of HCV is a major hurdle to the development of an 
effective therapy. The current standard therapy approved by the Food and Drug 
Administration (FDA) is the pegylated IFN-α 2a/ 2b combined with a nucleoside 
analogue, ribavirin.  However, sustained virological response (SVR) is only achieved in 
less than 40% of individuals infected with HCV genotypes 1 or 4, compared with 80% of 
patients infected with genotypes 2 or 3. Sequence variability within the NS5A region, 
particularly a consensus IFN sensitivity-determining region (ISDR) sequence and a PKR 
binding domain (Gale et al., 1998), have been associated with IFN alpha resistance in 
genotypes 1 and 4 (Kurosaki et al., 1997; Saiz et al., 1998; Pascu et al., 2004). IFN-
Ribavirin therapy requires a long time period (12-72 weeks) and is associated with 
significant side effects, including haemolytic anemia and severe depression (Fried and 
Hadziyannis, 2004). In a trial to improve the current therapy, alternative modified drugs 
were tested. For instance, taribavirin, a prodrug of ribavirin, reduced anemia, however the 
therapeutic efficiency was low (Gish et al., 2007). Therefore, alternative therapeutic 
approaches have evolved based on recent knowledge gained about the virus life cycle and 
the proteins involved in viral replication (Di Bisceglie et al., 2002; Keeffe, 2007; Soriano 
et al., 2008).  
 
1.9.2- Protease and polymerase inhibitors 
With increasing knowledge of the HCV life cycle, vital enzymes could be determined and 
targeted for inhibition. The NS3/NS4 protease and NS5B polymerase are the most 
attractive targets for antiviral therapy, as they are the key players in the viral life cycle. 
39 
 
Several compounds have already been tested against these vital proteins, and many have 
shown promising results (Narjes et al., 2003; Llinas-Brunet et al., 2004; Lamarre, et al., 
2003).  
 
1.9.3- RNA intereference 
RNA intereference (RNAi) is a mechanism by which long dsRNAs from an 
exogenous source like an invading virus or synthetic siRNA, or an endogenous source 
such as microRNAs (miRNAs), result in silencing of homologous gene expression.  
RNAi has been observed in most organisms and is considered an antiviral 
mechanism in plants and invertebrates (Ding et al., 2004). In mammalian cells, miRNAs 
have an essential role in regulating cellular gene expression (Szweykowska-Kulinska et 
al., 2003; Yang et al., 2005). Hundreds of miRNAs have been identified and 30% of 
proteins are regulated by miRNAs (Bartel et al., 2004).  
Utilization of RNAi technology seems appropriate for HCV therapy since the 
HCV genome is a single-stranded RNA that replicates in the cytoplasm of liver cells 
without integration into the host genome. Inhibition of HCV RNA translation could 
inhibit HCV replication, thus resolving chronic HCV infections.   
The major obstacle to successful use of RNAi technology is the extreme 
heterogeneity of HCV (Carmichael, 2002). The high error mutation rate of HCV 
facilitates escape from recognition and attack by siRNAs. Therefore, for efficient 
silencing, siRNAs must be targeted to conserved regions of the viral genome. The 5′ 
NCR of the HCV genome is the most conserved among all known strains of HCV. It is 
also critical for protein synthesis. Sequence-specific siRNAs, targeted to the IRES at the 
5' NCR, reduced viral protein synthesis and abolished intracellular replication of the viral 
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genomic RNA (Yokota et al., 2003). The NS3 coding region has also been shown to be 
an effective target, due to the high degree of conservation and accessibility of the RNA-
induced silencing complex (RISC). The NS3 region is vital for viral replication, as it 
encodes protease and helicase proteins. siRNAs against both NS3 and NS5b regions 
suppressed HCV replication (Takigawa et al., 2004), however NS5b is more 
heterogeneous than NS3.  
 siRNAs against structural genes have also been found to be an effective 
therapeutic option against HCV infection. siRNAs targeting the E1 and E2 genes and 
core gene demonstrated dramatically reduced HCV viral copy numbers in HCV serum-
infected human hepatoma (Huh-7) cells (Khaliq et al., 2010; 2011; Ansar et al., 2011).   
 Some cellular factors promote viral replication and biogenesis, making them ideal 
therapeutic targets. For instance, ADP-ribosylation factor 1 (Arf1) plays an important 
role in viral maintenance, thus downregulation of Arf1 expression by siRNA reduced 
both the levels of HCV RNA and the production of infectious viral particles in Huh7.5 
cells (Machlin et al., 2011). Taken together, these findings suggest RNAi as a potent 
therapy for the elimination of the HCV virus from persistently infected host cells. 
 
1.10- Hepatitis C vaccine 
Despite all the efforts towards HCV vaccine development, a vaccine is not yet 
available. Initially, the development of a vaccine against HCV was hampered by the lack 
of small animal models and a reliable cell culture system. The recent development of new 
HCV model systems, including HCV replicon cell lines (Lindenbach et al., 2005), has 
provided new avenues for vaccine development, and some progress has been made. Still, 
the most challenging obstacle remaining is the high mutation rate of HCV, which results 
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in multiple viral isolates. A successful vaccine must generate vigorous broad and multi-
specific CD4+ and CD8+ T cells, in addition to cross-genotype neutralizing antibodies 
(Inchauspe et al., 2007; Lang and Weiner, 2008).  
Since the immune response of many patients is impaired by the HCV infection, an 
HCV vaccine can also be used as a therapeutic tool to augment the immune system. 
Therapeutic HCV vaccines can be used with antiviral therapy or immunomodulators to 
expand their effect. Many vaccine strategies have been developed, including recombinant 
protein vaccines (Puig et al., 2004), DNA vaccines (Forns et al., 2000), and viral vector 
vaccines (Youn et al., 2008). Prime-boost strategies were also utilized including DNA 
prime followed by protein boost (Rollier, et al., 2004) or viral vaccine boost (Puig et al., 
2006; Youn et al., 2005). Therapeutic vaccines were also developed using peptide 
vaccines (Nevens et al., 2003; Klade et al., 2008) and some entered phase I clinical trials 
(Yutani et al., 2007). 
Initial vaccine research was based on recombinant proteins and showed promising 
results. For instance, HCV E1/E2 glycoprotein emulsified with MF59 (sub-micron oil-in-
water emulsion of a squalene adjuvant) induced a potent humoral immunity as evidenced 
by a strong CD4+ T cell response and specific neutralizing antibodies (O'Hagan et al., 
2004). However E1/E2 protein vaccine was able to induce a strong cytotoxic CD8+ T cell 
response when followed by a boost dose of defective alphaviral particles with RNA 
encoding for HCV E1/E2/NS3-5 (Lin et al., 2008). Several reports show that cellular 
immunity is critical for HCV clearance. This suggests that the DNA and viral vaccines 
are more effective as they induce both humoral and cellular immunity (Lechner et al., 
2000; Lauer and Walker, 2001). DNA vaccine technology provides a promising approach 
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that has several advantages over conventional vaccines and extensive research has been 
done to bring DNA vaccines to clinical use. Moreover, DNA vaccines have proven safe 
and immunogenic in several clinical trials. In addition, recombinant viral vaccine is 
another gene-based vaccine approach that combines the advantages of a DNA vaccine 
with a potent viral delivery system. Recombinant viral vaccines have also been tested in 
clinical trials as the primary vaccine or as a booster for a DNA vaccine.  
 
1.10.1- DNA Vaccines against HCV 
DNA vaccines have been used extensively in HCV vaccine research using 
different HCV genes. E1/E2 plasmid vaccines also triggered a Th1-like cellular immune 
response and increased IFN-γ secretion (Zhu et al., 2004). E2-encoding plasmid induced 
neutralizing antibodies (Owsianka et al., 2008) and a potent Th1 cellular response (Nam 
et al., 2006). Antigen localization has also been found to affect the outcome of vaccine 
administration. For instance, a secreted form of E2 enhanced the humoral immune 
response due to the availability of the protein to the immune pathways (Ma et al., 2002; 
Li et al., 2006). Optimizing cytosine-phosphate-guanine (CpG) motifs on the plasmid 
backbone has also been found to induce a significant increase in E2 antibody titers (Ma et 
al., 2002). Although the E2 antigen has been used due to its greater immunogenicity, E1 
antibodies showed broader reactivity. A multi-genotype vaccine encoding different 
genotypes of E1 was found to successfully induce cross-reactive immune responses both 
on the humoral and cellular levels (Encke et al., 2007). 
The highly conserved core antigen has also been considered as candidate immune 
target for the induction of a cross-reactive CTL response. Core encoded plasmid vaccines 
induced long-lasting humoral and cellular immune responses in mice (Lagging et al., 
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1995; Arichi et al., 2000; Duenas-Carrera et al., 2000) allowing them to enter clinical 
trials as therapeutic DNA vaccines in HCV-chronically infected patients (Alvarez-
Lajonchere et al., 2009). Administration of cytokines modulates the immune response. 
For instance, the CTL response elicited by the HCV core was enhanced when co-
administered with IL-2, and suppressed by IL-4 (Geissler et al., 1997). Multiple antigens 
were evaluated in a DNA vaccine encoding the structural genes E1/E2/core, inducing a 
potent CTL response (Nishimura et al., 1999).  However, core proteins were shown to 
interfere with the host immune response (Yoshida et al., 2001; Zhu et al., 2010) and to 
cause cellular transformation in mice (Moriya et al., 1998; Lerat et al., 2002).  
The NS3 protease/helicase is another attractive target. It is a large protein that 
potentially contains numerous epitopes. Moreover, NS3 and core antigens are the most 
conserved regions in the HCV genome. NS3 was extensively explored in DNA vaccines 
in small animals using various approaches. Plasmids encoding a codon-optimized NS3, 
with its cofactor NS4A, greatly enhanced CTL-mediated immunogenicity by increasing 
expression and intracellular stability of NS3 (Frelin et al., 2004; Ahlen et al., 2005). 
NS3/NS4A delivered by gene gun biased the balance towards a Th2 immune response 
(Frelin et al., 2003). Multigene vaccines encoding NS3, core and different genotypes of 
E1, have also been found to induce high cross reactive E1 antibody titers as well as high 
levels of specific NS3 and core CTL responses. These multigene vaccines also shift the 
immune response towards Th1, and induce high levels of IFN, and show robust 
prophylactic and therapeutic effects in mice (Zeng et al., 2009). 
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1.10.2- Recombinant viral vaccines against HCV 
Viral vectors with low virulence that express heterologous genes in the host were 
successfully used for vaccination, thus providing several advantages. The viral vector 
vaccines have the same advantages as DNA vaccines in intracellular production of the 
antigen, thus activating both cytotoxic T cells and the antibody response. However, they 
are preferred for their ability to infect various types of cells, including APCs (Miyazawa 
et al., 1999; Brown et al., 2003), and efficiently use the host cell machinery to induce 
high and prolonged foreign gene expression. Moreover, viral pathogen-associated 
molecular patterns (PAMPs) stimulate the innate immune response and work as adjuvants 
(Molinier-Frenkel et al., 2002).  
Several viral vectors have been used in HCV vaccination, including adenovirus, 
vaccinia virus and canarypox virus. Adenoviruses (Ad) were shown to be a highly 
efficient tool for vaccine delivery, due to their broad tropism. Ad vectors induce a CD8+ 
cytotoxic response, which is critical for HCV clearance. Immunization of mice with 109 
plaque forming units (PFU) of  recombinant adenovirus expressing NS3, induced NS3-
specific humoral and cellular responses, as well as CD8+-mediated protection against 
infection with the vaccinia virus expressing HCV polyproteins (Arribillaga et al., 2002). 
Co-administration of rAdNS3 vaccine with cytokines, like IL-12, or fusion of NS3 to 
stimulatory molecules, like the MHC class II chaperone protein invariant chain, results in 
a rapid, potent and prolonged cellular immune response in mice with production of    
IFN-γ, TNF-α and IL-2. This vaccine also protected mice from infection with vaccinia 
virus encoding heterologous HCV-NS3 (Mikkelsen et al., 2011).  
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One limitation to the Ad vaccine is the pre-existence of neutralizing antibodies 
against the commonly used Ad5 serotype in the majority of the human population. To 
overcome this problem, two studies looked at using alternative adenovirus serotypes, 
involving the immunization of rhesus macaques with HCV- NS genes expressed by the 
less prevalent serotype Ad6 (Capone et al., 2006), or with two heterologous Ad  vectors 
in a prime-boost strategy (Fattori et al., 2006). These strategies induced a robust, cross 
reactive cellular-mediated immune response against HCV antigens, lasting for 2 years, 
indicating the maintenance of memory cells.  
 
1.10.3- HCV Preclinical Vaccine Trials  
Encouraged by the positive results obtained in mouse studies, several vaccines were 
further assessed in chimpanzees, the only animal model susceptible to HCV infection. 
The initial HCV vaccine candidate, recombinant envelope glycoproteins (gpE1/E2) of 
HCV combined with an oil/water adjuvant, induced high levels of neutralizing antibodies 
and a Th1 cell response in chimpanzees. The incidence of chronic infection in immunized 
chimpanzees after their trial with the heterologous virus was substantially lower than in 
the unimmunized animals (Choo et al., 1994; Houghton et al., 1997). These promising 
results allowed this vaccine to proceed to a Phase 1 clinical trial.  
DNA-based vaccines encoding HCV envelope antigens E1 and E2 were also used 
in a prophylactic vaccine, inducing antibodies that could prevent persistence of the 
infection in chimpanzees injected with the homologous strain (Forns et al., 2000). 
Another approach is based on a DNA vaccine prime, encoding structural genes 
core/E1/E2 and nonstructural genes NS3/4/5 followed by a booster Ad vector expressing 
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NS3-5. This strategy induced high levels of specific humoral and cellular responses as 
well as a significant reduction in viral load after being challenged with the heterologous 
virus. Interestingly, the high E2 antibody response correlated with sterilizing immunity in 
one of the animals (Youn et al., 2005). Using NS genes NS3-NS5 in an adenovirus-based 
vaccine followed by electroporation of a plasmid encoding the same NS genes produced 
a high CTL cellular response, which could modulate the acute infection of heterologous 
virus-challenged animals. However, sterilizing immunity was not achieved due to the 
absence of neutralizing antibodies (Folgori et al., 2006).  
A new approach, based on non-infectious VLP, has demonstrated promising results. 
HCV VLPs were developed to mimic the natural virion, and to display the structural 
proteins on the surface, giving them the ability to infect host hepatocytes and to induce 
humoral and cellular immunity similar to the natural infection.  HCV VLPs were tested in 
chimpanzees and shown to control viremia in all animals challenged with a homologous 
strain of HCV (Elmowalid et al., 2007). 
Rollier et al., (2007) tested a heterologous prime boost strategy using core/ E1/E2 
and NS3 encoded by plasmids, as well as a modified vaccinia ankara virus (MVA). 
Challenge with the same HCV strain showed potent humoral and cellular responses that 
reduced viremia in acute infection, but failed to protect the animals from chronic 
infection. 
Chimpanzees immunized with replicating vaccinia virus encoding all the 5’ end of 
the HCV ORF, encompassing the capsid up until the NS3 gene, displayed a strong, long-
lasting NS3-specific cellular and humoral immune response. Challenging the animals 
with the same strain led to viral clearance, whereas the infection persisted when the 
47 
 
animals were injected with a pool of six heterologous strains, but at a very low level. This 
suggests that vaccinia virus is a promising vaccine candidate (Youn et al., 2008).  
 
1.10.4- HCV vaccine clinical trials  
 Promising preclinical results propelled HCV vaccines into clinical trials. Several 
vaccine approaches were tested in mice and chimpanzees, but only a few of them 
progressed to clinical trials. In this section, only the trials involving DNA-based vaccines, 
including plasmid or viral vectors will be emphasized.  
CICGB-230 was the first DNA-based vaccine to reach clinical trial for HCV 
infections. This Phase I trial took place in Cuba. The vaccine consisted of a combination 
of a plasmid expressing the HCV structural antigens (core/E1/E2), and core recombinant 
proteins.  CICGB-230 was evaluated by intramuscular (i.m.) injection in 15 patients 
chronically infected with the HCV genotype-1, who did not respond to the PEG-
IFN/ribavirin therapy. The course of immunization lasted six months. After immune 
system analysis, the immunization was shown to induce neutralizing antibodies and 
cellular immunity.  Although the viral load did not change, the patients showed 
stabilization or improvement in liver histology, and reduced fibrosis (Alvarez-Lajonchere 
et al., 2009).  
ChronVac-C, Tripep is another DNA vaccine evaluated in a clinical Phase I/IIa 
trial in Sweden. The vaccine was based on a plasmid encoding NS3/NS4A under the 
control of CMV ie promoter. The codons of NS3 were optimized to allow for enhanced 
expression in human cells. This vaccine was evaluated in 12 HCV patients infected with 
HCV genotype-1 who were not subjected to treatment, yet had a low viral load. The 
vaccine was administrated by i.m. injection, followed by in vivo electroporation, to 
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enhance the antigen uptake. The preliminary results demonstrated the development of    
T-cell response that was correlated to a reduction in the viral load in patients who 
received a higher dose. Moreover, the vaccine was proven to be safe (Sallberg et al., 
2009). 
 Ad vectors were also evaluated as a prophylactic vaccine in a Phase I trial.  The 
vaccine was based on a replication defective adenovirus expressing NS3-NS5, with an 
inactivated HCV polymerase, to ensure safety.  Healthy volunteers were immunized with 
two heterologous Ad vectors from rare serotypes, human Ad6 and the simian AdCh3, to 
overcome the problem of pre-existing anti-Ad antibodies. The prime-boost regime was 
shown to be highly immunogenic, with limited side effects. The Ad vaccine induced 
potent multi-specific CD4+ and CD8+ immune responses, as well as long lived memory T 
cells (Barnes et al., 2009; 2012).  
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THE PROJECT GOALS 
 
As seen in the review, a vaccine against HCV remains elusive partly due to virus 
diversity and partly due to the inefficiency of the current vaccine approaches explored to 
date. Although a great deal of research was done and promising results were obtained, no 
HCV vaccine is currently available. The goal of this project is to evaluate three different 
approaches for vaccination and treament against HCV as follows:  
1- Evaluate two Ad promoters MLP, and AdE1A, compared to CMV ie promoter, 
and study their effect on the efficacy of DNA vaccines encoding the HCV genes 
E1 and NS3.  
2- Evaluate an adenovirus vaccine encoding HCV NS3.  
3- Evaluate siRNA sequences against the NS3 region and study their efficiency for 
the inhibition of NS3.  
4- In addition, miRNAs are evaluated as novel parameters to measure the immune 
response elicited by the immunization. 
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   Chapter 2 
PROMOTER EFFECT ON DNA VACCINE EFFICACY  
2.1- Introduction 
DNA vaccination is a promising approach that depends on the delivery and 
expression of the antigen in the host cell. Thus DNA vaccines induce both humoral and 
cellular immune responses. DNA vaccination is an ideal approach for protection against 
HCV, particularly given the difficulty in growing HCV in cell culture for a live vaccine. 
In addition, evidence has shown that cellular immunity plays a critical role in HCV 
clearance (Thimme et al., 2002; 2008; Rehermann et al., 2005) and neutralizing 
antibodies are of vital importance in preventing HCV infection (Cooper et al., 1999). 
Viral genetic diversity represents a major challenge to vaccine development (Timm et al., 
2007). Therefore, choosing the correct antigen is critical in order to design an effective 
DNA vaccine. Antigen targets should be highly conserved and immunogenic. The NS3 
gene is the most conserved region in the viral genome and induces a strong immune 
response. E1 is a good target for neutralizing antibodies, due to its limited variability and 
inter-genotype cross-reactivity compared to E2 (Zibert et al., 1997). Furthermore, the 
function of E1 was found to be impaired in chronic HCV infection, suggesting a role in 
viral clearance (Depraetere and Leroux-Roels, 1999). Therefore, NS3 and E1 are ideal 
candidates for a prophylactic and therapeutic vaccine capable of eliciting a cellular 
immune response that prevents the infection and eliminates the infected cells (Ward et 
al., 2002; Shoukry et al., 2004).  
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DNA vaccines were evaluated against several viruses and successfully produced 
protective immunity in small animals but they showed lower efficacy in large animals 
and humans. Subsequently, a number of strategies were employed to enhance the efficacy 
of DNA vaccines. These approaches include improving antigen expression and stability, 
addition of adjuvants and immune modulators, using different delivery methods and 
routes, codon optimization and heterogeneous boosting (reviewed in Manoj et al., 2004). 
Antigen expression level is an important factor affecting the immune response triggered 
by DNA vaccines that has yet to be optimized. Antigen levels are influenced by 
promoters.  Most studies of DNA vaccines have utilized standard promoters. The most 
widely used is the immediate early cytomegalovirus promoter (CMV ie) due to its strong 
constitutive activity in most cell types (Boshart et al., 1985; Furth et al., 1991; Mao et al., 
2008). Therefore, the effect of different promoters on the efficiency of DNA vaccines 
against HCV was evaluated in this thesis. Two different Ad promoters were tested, the 
weak immediate early E1A promoter (E1AP) and the strong major late promoter (MLP), 
and these results were compared to the standard CMV ie promoter. 
E1Ap is a weak immediate early promoter responsible for transcription of the 
early region E1A of Ad. The transcription of the E1A region is initiated immediately 
after infection, since it depends on cellular transcription factors (Nevins et al., 1979). The 
maximal and early activity of the E1A promoter is due to the interaction of cellular 
transcription factors E2F (Kovesdi et al., 1987) and EF-1A (Bruder and Hearing, 1989) 
with the enhancer elements of the promoter. 
The MLP drives transcription of the major transcriptional unit of Ad which 
encodes the structural proteins required for virion assembly. The activity of MLP is weak 
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during the early phase of adenovirus infection, and greatly increases during the late 
infection, following viral DNA replication (Shaw and Ziff, 1980).  
In this study, plasmids were constructed encoding HCV antigens NS3 or E1, 
under the control of the three promoters, CMV ie, MLP and E1AP. The effects of 
promoters on antigen expression as well as the antibody level were evaluated. In addition, 
microRNAs that are involved in immune response regulation were evaluated as indicators 
of the immune response. 
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2.2- Methods 
 
2.2.1- Amplification of HCV genes NS3 and E1 
HCV cDNAs, NS3 and E1, were obtained by RT-PCR amplification from the 
total RNA of the Huh7.5-Con1/FL-Neo cell line harboring the HCV viral genome of 1b 
genotype (a kind gift from Dr. Rice, Rockefeller University, USA). Two hundred 
nanograms of total RNA was used in a 20 µL reverse transcription (RT) reaction using 
NS3 or E1 specific RT primers. Four microliters of the cDNA was used in a PCR 
reaction with 0.12 μL of forward and reverse primers (50 μM stock), 0.2 μL 
deoxynucleotide triphosphates (dNTPs) (10 mM). The reaction program started with 
initial denaturation for 5 min at 95ο C. This was followed by 35 cycles, each consisting of 
denaturation at 95ο C for 30 sec, annealing for 30 sec at the appropriate temperature, and 
extension at 72ο C for 1-2 min (1 min for a 500 bp fragment) using Pfu polymerase 
(Fermentas). At the end of the reaction, the final extension cycle was performed at 72º C 
for 10 min. The primers were designed using the sequence of the HCV-1b strain from the 
nucleotide database at http://www.ncbi.nlm.nih.gov/nuccore (GenBank: AJ238799.1) and 
ordered from Sigma Genosys. Each fragment was designed to have an NcoI and BamHI 
restriction site, as well as start and stop codons in the forward and reverse primer, 
respectively, to facilitate cloning and expression. NS3 is CG rich, with long CG stretches 
over the entire gene. It also has a strong secondary structure. Therefore, 5% dimethyl 
sulfoxide (DMSO) (Roche Applied Science) was added to the PCR reaction to inhibit the 
secondary structure. In addition NS3 was amplified in 2 parts that were ligated at 
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overlapping region after digestion with AvrII.  Figure 2.1 shows the HCV genome. All 
primers used for this chapter are listed in Table 2.1. 
 
 
 
 
 
 
Figure 2.1: Schematic diagram of the HCV genome showing the location and sizes of E1 
and NS3. Truncated E1 and complete NS3 were amplified by RT-PCR from the total 
RNA of HCV permissive cells (Con1/FL-Neo). 
 
2.2.2- Plasmid construction 
NS3 and E1 cDNAs were separately cloned under 3 different promoters, CMV ie, 
MLP, and E1A. The E1Ap plasmid was constructed by cloning adenovirus E1A promoter 
and poly A fragments in pUC19.  pMTGA and pCG (Norgen Biotek corp.) were plasmids 
containing the MLP and CMV ie promoter respectively. The cDNAs were inserted in 
NcoI and BamHI restriction sites under E1A and MLP and in AgeI and NotI under the 
CMV ie promoter. All plasmids were confirmed by restriction digestion and sequencing. 
Small-scale plasmid DNA isolation was carried out using the Plasmid DNA MiniPrep Kit 
(Norgen Biotek Corp.) according to the manufacturer’s instructions. Large scale 
endotoxin free plasmid DNA was prepared using Endotoxin Free Plasmid DNA 
MaxiPrep Kit (Norgen Biotek Corp.) according to the manufacturer’s instructions. The 
plasmid DNA was concentrated by ethanol precipitation and resuspended in endotoxin 
free phosphate buffer saline (PBS) to a final concentration of 1 mg/ mL.  
HCV 1b 
9605 bp
core 
E1
E2
P7
NS2 
NS3 
NS4a 
NS4b NS5a NS5b 
HVR1
HVR2
3'UTR5'UTR (576 bp)   (1893 bp)  
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2.2.3- Cell culture  
2.2.3.1- Cells and maintenance 
The cells used for in vitro analysis throughout the course of this work include 
Con1/FL-Neo cells, and HEK 293 cells.  
Con1/FL-Neo, a sub-line of human hepatoma cells containing the HCV strain 1b 
subgenomic RNA replicon, was a kind gift from Dr. Rice (Rockefeller University, USA). 
Cells were maintained in Dulbecco’s modified Eagle medium (DMEM) (Invitrogen 
Corp., Gibco®), supplemented with 10% fetal bovine serum (FBS) (Hyclone), non-
essential amino acids (Invitrogen Corp., Gibco®), 750 mL G418 sulphate (CalBiochem), 
100 units/mL penicillin, and 100 µg/mL streptomycin (Invitrogen Corp., Gibco®), at 37° 
C in 5% CO2. Cells were passaged every 3 days, at a split ratio of 1:2 after treatment with 
0.05% trypsin and 0.02% EDTA (Blight, et al., 2002).  
HEK 293 cells (Graham et al., 1977; Microbix Inc., ATCC CRL-1573) were 
maintained in minimum essential medium (MEM) (Invitrogen) supplemented with 10% 
(v/v) FBS (Hyclone), 1% (v/v) Antibiotic-Antimycotic (10,000 units/mL penicillin G 
sodium, 10,000 μg/mL streptomycin sulfate, and 25 μg/mL amphotericin B; Invitrogen 
Corp., Gibco®), 1% GLUTAMAXTM-1 (Invitrogen Corp., Gibco®), 3% (v/v) sodium 
bicarbonate (Invitrogen Corp., Gibco®), at 37° C in 5% CO2. HEK 293 cells were 
passaged every 3 days at a split ratio of 1:2 after treatment with saline citrate (15 mM 
sodium citrate, 135 mM potassium chloride). 
2.2.3.2- Cell cryopreservation and thawing 
For keeping cell stock, cells were frozen when they grew to the late log phase 
(when the cell monolayer was 90% confluent).  The cells were detached, counted and 
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centrifuged at 200 x g for 5 min at 4° C and then resuspended in FBS containing 10% 
DMSO at a concentration of 2 x 106 cells/mL.  The cell suspension was aliquoted into 
cryovials (Sarstedt) and slowly frozen by wrapping them in insulating tissue towel, 
followed by storage at -70° C. When thawing frozen cells, the cells were removed 
quickly from storage and thawed in a 37° C water bath.  The cells were diluted in 10 mL 
of growth medium, and centrifuged at 200 x g for 5 min. The cell pellet was resuspended 
in 20 mL of complete growth medium, plated on a 100 mm tissue culture plate and 
incubated at 37° C with 5% CO2.  
 
2.2.3.3- Mammalian cell counting 
The cells were lifted and resuspended in the proper medium. The cell suspension 
was counted using a hemocytometer (Improved Neubauer, Hausser Scientific) under an 
inverted light microscope, and the number of total cells in the original suspension was 
calculated according to the equation: 
Cell concentration/mL = Total cell count in the 4 large corner squares x 2500 x dilution 
factor. 
2.2.3.4- Mammalian cell transfection 
HEK 293 cells were transfected with different plasmids encoding E1 and NS3 to 
evaluate the promoter effect on gene expression. When the cells were 80-90 % confluent, 
they were transiently transfected with endotoxin free plasmid using lipofectamine 2000 
(Invitrogen Corp., Gibco®) according to the manufacturer’s instructions. Briefly, the 
cells were plated in antibiotic-free medium to avoid cytotoxicity. For a 6-well plate, 500 
μL transfection mix was used per well. Five microliters of lipofectamine was diluted in 
250 μL Opti-MEM I Reduced Serum Medium (Invitrogen Corp., Gibco®) and incubated 
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for 5 min at room temperature. It was then mixed with 250 μL of Opti-MEM I Medium 
containing 5 μg of the plasmid DNA. The mix was incubated for 20 min before being 
added dropwise to the well. The cells were incubated for 6 h followed by changing of the 
medium with the complete medium containing an antibiotic. 
 
2.2.4- In vitro evaluation of transcriptional activity of different promoters 
2.2.4.1- RNA isolation 
Total RNA was isolated using the Total RNA Purification Kit (Norgen Biotek 
Corp.) according to the manufacturer’s instructions. 
 
 2.2.4.2- RNA quantification 
RNA was quantified using a spectrophotometer after dilution with water. The 
absorbencies were measured at wavelengths 260 nm (A260) and 280 nm (A280) and the 
RNA concentration was then calculated according to the following formula (Sambrook et 
al., 1989): RNA concentration (μg/ μL) = (A260) × (dilution factor) × (40 ng/ μL)/1000. 
The ratio A260/A280 was used to assess RNA purity. An A260/A280 ratio of 1.8- 2.1 is 
indicative of highly purified RNA. 
2.2.4.3- Formaldehyde agarose gel electrophoresis 
The quality of RNA samples was also assessed by electrophoresis on a formaldehyde 
agarose gel, prepared according to Sambrook et al. (1989). The gel was viewed under UV 
light and images were captured with AlphaImager 2200 (Alpha Innotech). 
2.2.4.4- DNAse I treatment and cleaning of RNA 
 
The DNA contamination in the isolated RNA samples was degraded with TURBO 
deoxyribonuclease (DNaseI) (Ambion). Fifty microlitres of each RNA sample was 
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digested in a 100 µL reaction mixture containing the provided buffer and 4 units of 
TURBO DNaseI, then incubated at 37° C for 30 min. RNA samples were cleaned after 
DNase I treatment with the RNA Clean Up and Concentration Kit (Norgen Biotek Corp.), 
according to the manufacturer’s instructions. 
 
2.2.4.5- Quantitative RT-PCR: 
The quantitative (q) RT-PCR was performed to quantify the transcription levels of 
NS3 and E1 under different promoters. The RT reaction was performed using 200 ng of  
RNA combined with 0.5 µL RT-specific primer (50 mM stock) in 5 µL final volume. 
This mixture was incubated for 5 min at 70° C, and then cooled at 4° C. Fifteen 
microliters of the RT reaction solution was added to the mixture. The RT reaction 
solution contained 4 μL of 5X First Strand Buffer (250 mM Tris-HCl pH 8.3, 375 mM 
KCl and 15 mM MgCl2), 2 μL of 0.1 M Dithiothreitol (DTT), 1 μL of 10 mM dNTPs, 
0.1 μL Superscript III reverse transcriptase (Invitrogen) and 7.9 μL RNase/DNase-free 
water. The reaction was incubated at 25° C for 5 min, followed by 90 min at 50° C. The 
reaction was inactivated by heating at 70° C for 15 min and finally held at 4° C.   
 The q-PCR reaction was performed in a Bio-Rad iCycler thermal cycler. Briefly, 
for 20 μL total reaction volume, 10 μL of 2 x CYBR GREEN master mix (BioRad) was 
mixed with 1.2 μL of forward and reverse primers (5mM stock) and 4 μL of cDNA 
template. The q-PCR reaction starts with 15 min at 95ο C followed by 40 cycles of three 
steps: 95ο C for 15 sec, 60ο C for 30 sec and 72ο C for 30 sec. The reaction was incubated 
for 1 min at 57ο C before starting a melting curve analysis by 0.5ο C increments every 10 
sec over 80 rounds. Gene transcription levels were determined using absolute 
quantification. A standard curve was prepared from NS3 or E1 plasmid using known 
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concentrations. The concentration of unknown samples was then determined by simple 
interpolation of cycle threshold (Ct) values into the standard curve. 
 
Table 2.1: List of the primers used for construction and q-PCR  
Replicon Primer Sequence amplicon size 
E1A 
promoter 
E1P3Fw 5' ATATATCATATGGACGGATGTGGCAAAAGTGA  3' 
435 bp 
E1P2 Rv 5' AAGAATTCCCATGGTTTCAGTCCCGGTGTCGGAG  3' 
E1A 
prolyA 
PolyA Fw 5' CTGCAGGGTGTAAACCTGTGATTGC 3' 
180 bp 
polyA Rv 5' AAGCTTAGGTCAGATGTAACCAAGAT 3' 
HCV-E1 
for 
cloning 
conE1-RT 5' GTCAACGCCGGCAAAGAGTAG 3' 
conE1RS-Fw 5' GCATGCCATGGGATATGAAGTGCGCAACGTATC 3'  
488 bp 
conE1tRS-RV 5'CGATGATTGCGGCCGCTTAGATCCGGAGTAACTGCGATA3' 
HCV-E1   
for        
q-PCR 
conE1-Fw 5' ATGTATGAAGTGCGCAACGTATCC 3' 
457 bp 
conE1tr-RV 5' TTAGATCCGGAGTAACTGCGATACC 3' 
HCV-
NS3 for 
cloning 
RT-NS3con1 5' GCTCGTGACGACCTCCAG 3' 
HCNS3-1Fw 5' CACCCTGCCATGGCGCCTATTACGGCCTACTC 3' 
780 bp 
HCNS3-1Rv 5' CAATTATTGCGGCCGCTAAGGGTCGATACCATGTGCC 3' 
HCNS3-2Fw 5' GCATGCCATGGCAGCCCAAGGGTATAAGGT 3' 
1270 bp 
HCVNS3-Rv 5' CGATGATTGCGGCCGCTACGTGACGACCTCCAGGT 3' 
HCV-
NS3 for 
q-PCR 
NS31Fw 5' CCAAATGTACACCAATGTGGACC 3' 
283 bp 
NS31Rv 5' TGGTTTCCATAGACTCGACGG  3' 
NS32Fw 5' GCTGTGCTTGGTACGAGCTC 3' 
396 bp 
NS32Rv 5' AGCCGTATGAGACACTTCCAC  3' 
 
 
 
60 
 
2.2.5- Expression of E1 and NS3 proteins 
2.2.5.1- Protein expression 
 NS3 and E1 were expressed in E.coli expression strain BL21(DE3)pLysS 
(Novagen). E1 and NS3 were cloned under the T7 promoter in 2 plasmids, pT7E1 and 
pT7NS3. The plasmid encoding the gene of interest was transformed in pLysS bacteria. 
One colony was suspended in 2 mL Luria-Bertani (LB) media, containing 1 μg/ mL 
ampicillin and 34 μg/ mL chloramphenicol, and cultured overnight in a shaking incubator 
at 37ο C. The culture was inoculated in 50 mL LB, and grown until the OD600          
reached ~0.6. The culture was then centrifuged for 10 min at 4000 rpm. The pellet was 
suspended in 1L LB, and was then grown once again. When the OD600 reached ~0.6, the 
culture was induced by 0.5 mL of 50 mM isopropyl-beta-D-thiogalactopyranoside 
(IPTG) and incubated for an additional 3 h in a shaking incubator at 37○ C. 
2.2.5.2- Protein isolation from inclusion bodies 
The expressed protein was isolated from the culture of the pLysS strain after 
IPTG induction. The isolation was carried out using the ProteoSpin Inclusion Body 
Protein Isolation Maxi Kit (Norgen Biotek Corp) according to the manufacturer’s 
instructions. 
2.2.5.3- Protein gel electrophoresis  
 Proteins were separated using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). ProteoLadder 125 or 150 (Norgen Biotek. Corp)  was used 
to determine the protein molecular weight. The polyacrylamide stock solution was 
prepared to an acrylamide concentration of 30% w/v at a ratio of 29 acrylamide:               
1 bisacrylamide (Sambrook et al., 1989). Prior to gel loading, the protein samples were 
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prepared by heating for 10 min at 90○C in a protein loading dye (125 mM Tris-HCL pH 
6.8, 10% 2-mercaptoethanol, 10% SDS, 10% glycerol and 1% bromophenol blue).  The 
gel was run at 15 V/cm in Tris-glycine electrophoretic buffer (25mM Tris, 25mM glycine 
[pH 8.3] and 0.1% SDS). The gel was stained with Coomasie Brilliant Blue R250 (0.25% 
[w/v] dissolved in 45% methanol, and 10% glacial acetic acid) for 2 h. After rinsing, the 
gel was incubated in destaining solution (45% methanol, 10% glacial acetic acid) 
overnight with agitation.  
2.2.5.4- Protein quantification (Bradford assay) 
The BioRad colorimetric reagent, based on the Bradford assay (Bradford, 1976), 
was used to determine the concentration of protein extracts. In this assay, a set of 
standards was created from bovine serum albumin (BSA) (NEB) with different 
concentrations. T he standards and the unknown protein sample were mixed with the 
Bradford reagent, and the absorbance of the resultant blue color was measured at 595 nm 
following a short incubation at room-temperature. A standard curve was constructed 
using the standard OD values, and the concentration of the protein samples was 
determined based on the equation of the line, generated from the standard curve. 
2.2.6- Animals and immunization protocol 
Female BALB/c mice, 6-8 weeks old, (18-20 g) were purchased from Charles 
River Breeding Laboratories, and were housed at the animal care facilities at Brock 
University. All animal work was approved by the Brock University Animal Care and Use 
Committee (ACC) and done according to the Canadian Council on Animal Care (CCAC) 
guidelines required for experimentation with animals. Three animals were used in each 
group. Immunization with the DNA vaccines was accomplished by injecting 50 µg of 
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plasmid DNA (in 100 µL final volume of endotoxin free PBS) into the tibialis anterior 
(TA) muscle, divided on the left and right muscles. Each animal received three i.m. 
injections, at two-week intervals. The control animals were injected with 100 µL PBS.  
Mice were anaesthetized by inhalation of 5% isoflurane with oxygen prior to injection.  
2.2.7- Blood collection and serum preparation 
Blood samples were collected by heart puncture 2 wks after the last 
immunization. The blood was incubated in an upright position at room temperature for 
30-45 min to allow for clotting, and then centrifuged at 7000 x g for 15 min at 4ο C. The 
serum (supernatant) was collected and small aliquots were stored at -80ο C. 
2.2.8- Immunological analysis 
2.2.8.1- Enzyme-linked immunosorbent assay (ELISA) 
An ELISA test was used to monitor the levels of NS3 and E1 specific antibodies 
in the sera collected from the immunized animals (Zeng et al., 2009). ELISA Immulon 
4HBX plates (96-well) (VWR International, LLC) were coated with recombinant NS3 or 
E1 protein (expressed in E.coli) at 0.1µg/well in a carbonate buffer (50 mM NaHCO3 
buffer, pH 9.6) overnight at 4ο C. The plate was washed 5 times with wash Phosphate 
Buffered Saline (PBS) (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4 and1.47 mM 
KH2PO4, pH of 7.4) + 0.1% Tween 20. The active sites on the plates were blocked with 
wash solution containing 2% BSA for 2 h at room temperature to block non-specific 
antibody binding. Serial dilutions of the sera were incubated with the protein for 2 h at 
room temperature on an orbital shaker. To determine the IgG levels, 100 µL of 
Peroxidase-conjugate goat anti-mouse IgG antibody (Sigma) at a dilution of 1:5000 was 
added to each well. The reactions were developed with o-phenylenediamine 
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dihydrochloride (OPD) substrate (Sigma) at 200 μL/well followed by 30 min incubation 
at room temperature. The optical density (OD) was measured at 450 nm by the Thermo 
Scientific® ELISA reader. OD values had to be at least twice the values of the control 
(non-immunized) animals to be considered positive (Zhu et al., 2004). 
2.2.8.2- Protein immunoblot (western blot) 
Western blot assays were performed to confirm the specificity of NS3 and E1 
antibodies in the serum of the immunized mice (Brett et al., 2004). Briefly, the proteins 
were separated on a 10% SDS-polyacrylamide gel followed by electrophoretic transfer to 
a polyvinylidene difluoride (PVDF) membrane (Pall Sciences). The membrane was 
soaked in methanol, followed by soaking in 1X Blotting Buffer (25 mM Tris, 192 mM 
glycine, 10% methanol) (Towbin et al., 1979) along with the blotting paper, and the gel 
containing the protein. The transfer unit was then assembled according to the 
manufacturer’s instructions, and the proteins were transferred to the PVDF membrane at 
40 mA per gel for 1 h.  The PVDF was then blocked overnight using 5% powdered milk 
in TBST buffer (50 mM Tris base, 150 mM NaCl, 0.05% Tween 20, pH 7.6), washed 3 
times with TBST, and incubated for 2 h with pooled serum from an animal group (diluted 
to 1:500 in TBST with 0.5% milk). After washing, the PVDF membrane was hybridized 
with 1/2500 dilution of horse radish peroxidase (HRP)-conjugated anti-mouse IgG 
(Sigma). The membrane was washed and developed by chemiluminescent detection using 
the Pierce CN/DAB Kit (Thermo Fisher Scientific).  
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2.2.8.3- Quantification of serum miRNA levels  
Total RNA was isolated using the Total RNA Purification Kit (Norgen Biotek 
Corp.) The expression levels of different miRNAs were quantified by qRT-PCR using 
specific primers. The RT reaction was performed using stem–loop RT primers specific 
for each miRNA. The q-PCR reaction was carried out using specific forward primers for 
each miRNA and one universal reverse primer (miRNA-RV) complementary to the stem 
loop (table 2.2). The Ct values were normalized to the 5SrRNA gene. The fold change 
values were calculated with the ΔΔCt method. The expression levels of miRNAs were 
indicated as fold-difference in expression compared to the non-immunized animals.  
 
Table 2.2: The primers used for miRNA quantification 
PCR 
product Primer Sequence 
 miRNA-RV   5’ GTGCAGGGTCCGAGGT 3’ 
mir-181  
mir-181-RT     5’ GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACTCAC 3’ 
mir-181-Fw    5’ AACATTCAACGCTGTCGGT 3’ 
mir-155 
mir-155-RT   5’ GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACCCCT 3’  
mir-155-Fw   5’ TTAATGCTAATTGTGATAGGGGT 3’  
mir-196 
mir-196-RT     5’ GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCCCAAC 3’ 
mir-196-Fw   5’  TAGGTAGTTTCCTGTTGTTGGG 3’ 
mir-296 
mir-296-RT    5’ GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACAGGA 3’ 
mir-296-Fw    5’ AGGGCCCCCCCTCAAT 3’ 
mir-21 
mir-21-RT     5’ GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACACAGTT 3’ 
mir-21-Fw    5’  TAGCTTATCAGACTGATGTTGA  3’ 
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2.3- Results 
2.3.1- PCR Amplification of HCV NS3 and E1 Genes 
E1 and NS3 cDNA were amplified from Con1/FL-Neo cells. The PCR products 
were confirmed by gel electrophoresis and sequencing. The PCR products of E1 (448 bp) 
and NS3, amplified in 2 parts, (780 and 1270 bp) are shown in Figure 2.2.  
 
  
 
 
 
 
Figure 2.2: Agarose gels showing the PCR product of HCV genes. Gel (A) E1 PCR 
product (488 bp). L is Norgen’s FastRunner ladder. Gel (B) - NS3 PCR products: NS3-1 
(780 bp) and NS3-2 (1270 bp). L is Norgen’s MidRanger ladder. The Control lane 
contains the negative control (no template). E1 and NS3 were amplified from Con1/FL-
Neo cells expressing a subgenomic replicon of HCV. Size of the ladder bands are 
indicated in base pairs (bp). 
 
2.3.2- Cloning of HCV-E1 and NS3 under different promoters 
2.3.2.1- Construction of Ad E1A promoter plasmid 
The plasmid containing Ad E1A promoter (E1AP) and E1A polyadenylation (pA) 
signal were designed based on pUC19. The strategy is shown in Figure 2.3.  E1AP and 
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HindIII (628) 
CTGCA AAGCT 
PstI HindI
 
E1A polyA  
          
ligation 
PstI/HindIII PstI/HindIII 
NdeI 
CATATG 
NcoI    EcoRI 
E1A promoter 
PCR product (435 bp) 
GAATTC 
NdeI/ EcoRI 
ligation 
NdeI/ EcoRI 
pUC19 
2686  
AP r
ALPHA P(BLA) 
P(LAC) 
ORI 
Pst I (440) 
Hin d III (448) 
EcoR I (397) 
pE1A poly A 
2866 bp 
APr 
poly A 
ORI 
NdeI (185) 
Pst I (437) 
pE1AP 
3072 bp 
APr 
poly A 
E1Ap 
P(BLA) 
ORI 
Eco RI (603) 
Nco I (597) 
Nde  I (185) 
Pst I (643) 
Hin dIII (834) 
pA were amplified from pFG173, a plasmid containing most of the Ad5 genome. The 
resultant plasmid, designated as pE1P, was confirmed with sequencing.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Schematic diagram showing the strategy for constructing the pE1Ap plasmid 
containing the adenoviral E1A promoter and polyA signal. The promoter and polyA was 
amplified from the adenovirus plasmid pFG173, and cloned in pUC19. 
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2.3.2.2- Cloning of HCV- E1 and NS3 under Ad5-E1A promoter 
Two plasmids encoding HCV-E1 and HCV-NS3 under the control of Ad E1A 
promoter were constructed. The PCR fragments E1 or NS3 were ligated in pE1p as 
shown in Figures 2.4 and 2.6. The resultant plasmids, pEE1 and pENS3, were confirmed 
with restriction enzyme digestion and sequencing. Figures 2.5 and 2.7 show the 
confirmation of pEE1 and pENS3 respectively.  
As shown in the gel, when plasmids pEE1 and pENS3 were digested with several 
restriction enzymes, the observed bands were similar to what is expected. Extra bands are 
possibly resultant from non-digested plasmid, e.g. a band of about under 4000 bp in lane 
1 (Figure 2.5), a band of 3000 bp in lane 2 and a band of about 5000 bp in lane 3 (Figure 
2.7). 
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Figure 2.4: Schematic diagram showing the strategy for constructing the pEE1 plasmid. 
The HCV-E1 gene was amplified from Con1/Fl-Neo cells and cloned in pE1A under the 
control of the adenoviral E1A promoter and polyA signal.   
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3519 bp 
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Table 2.3: Restriction enzyme analysis of pEE1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5: Confirmation of pEE1 by restriction enzyme digestion. (A) pEE1 plasmid 
map showing the restriction enzyme recognition sites. (B) Restriction enzyme digestion 
of pEE1on an agarose gel. L: Norgen’s MidRanger ladder; Lane 1-3: plasmid DNA 
digested by restriction enzymes as shown in table 2.3. The size of ladder bands is shown 
in bp. 
Lane 
number Enzyme 
Expected band 
size (bp) 
1 AvaI/ ZraI 2746, 773 
2 NsiI/  HindIII 2940, 557 
3 NdeI/ MfeI 2755, 764 
(A) 
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E1A polyA
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Figure 2.6: Schematic diagram showing the strategy for constructing the pENS3 
plasmid. HCV-NS3 cDNA was amplified from Con1/Fl-Neo cells expressing the HCV 
genome, and was cloned under the control of adenoviral E1A promoter and polyA signal 
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Table 2.4: Restriction enzyme analysis of pENS3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: Confirmation of pENS3 by restriction enzyme digestion. (A) pENS3 plasmid 
map showing the restriction enzyme recognition sites. B) Restriction enzyme digestion of 
pENS3 on an agarose gel. L: Norgen’s MidRanger marker; Lanes numbered 1-5: plasmid 
DNA digested by restriction enzymes as shown in Table 2.4. The size of ladder bands is 
shown in bp.  
Lane Restriction enzyme 
Expected band  
size (bp) 
1 HindIII/AvrII 3544/ 1390 
2 NdeI/ SalI 3234/ 1722 
3 ZraI 3074/ 1882 
4 BsrG1 4363/ 593 
(A) 
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2.3.2.3. Cloning of HCV-E1 and NS3 under Ad5-MLP promoter 
E1 and NS3 were also cloned under the control of MLP. The backbone was 
derived from the pMTGA plasmid, which contains Ad5-MLP followed by the Ad 
tripartite sequence. The polyA signal of pMTGA was derived from simian virus 40 
(SV40). E1 and NS3 were cloned under control of MLP to generate pMTE1 and 
pMTNS3 respectively. The schematic strategies are shown in Figures 2.8 and 2.10 
respectively. Both plasmids were confirmed with restriction enzyme digestion and 
sequencing. The digestion results of the plasmids are shown in Figures 2.9 and 2.11. The 
results showed that pMTE1 and pMTNS3 were digested with several restriction enzymes 
and the observed bands are as expected from restriction analysis. Extra bands in lanes 4 
and 5 of about 4000 bp (Figure 2.9) and lane 3 of 5000 bp (Figure 2.11) possibly result 
from non-digested plasmid. Sequencing results showed no mutations in the constructs. 
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NcoI- BamHI 
ligation 
pMTE1 
3630 bp 
AP r
pA 
MLP 
TPL 
E1 
ORI 
Nco   I (862) 
BamH I (388) 
NcoIH BamHI 
E1 488bp 
NcoI (1120) 
BamH I (397) 
pMTGA 
3888 bp 
AP r
GFP 
pA 
MLP 
ORI 
TPL 
 
 
 
 
 
 
 
 
 
  
   
  
  
 
 
 
 
 
 
Figure 2.8: Schematic diagram showing the strategy for constructing pMTE1 plasmid. 
HCV-E1 gene was amplified from Con1/Fl-Neo cells and cloned under the control of the 
MLP promoter and SV40 polyA signal. 
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Table 2.5:  Restriction enzyme analysis of pMTE1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9: Confirmation of pMTE1 by restriction enzyme digestion. (A) pMTE1 
plasmid map showing the restriction enzyme recognition sites. (B) Restriction enzyme 
digestion of pMTE1 on an agarose gel. L: Norgen MidRanger Ladder; Lanes numbered 
1-5: plasmid DNA digested by restriction enzymes as shown in Table 2.5.  The size of 
ladder bands is shown in bp.  
 
 
Lane Restriction enzymes 
Expected band  
size (bp) 
1 EcoRI 2935, 695 
2 MfeI 3364, 266 
3 NcoI, NotI 3165, 465 
4 BamHI, NsiI 3253, 377 
5 PstI, NheI 2917, 713 
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pMTNS3 
5067 bp 
AP r
pA 
MLP 
TPL 
NS3 
ORI 
Nco I (2299) 
BamH I (388) 
pMTGA 
3888 bp 
AP r
GFP 
pA 
MLP 
ORI 
TPL 
Nco  I (1120) 
BamH I (388) 
NcoI BamHI 
NS3 
1900 bp 
NcoI/ BamHI 
ligation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10: Schematic diagram showing the strategy for constructing pMTNS3 plasmid. 
The plasmid contains the HCV-E1 gene under the control of the MLP promoter and 
SV40 polyA signal. 
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pMTNS3 
5067 bp 
AP r pA 
MLP 
TPL 
NS3 
P(BLA) 
ORI 
Avr II(1590) 
Mfe I (244) 
Pst I (2821) 
AccI (990) 
BamHI (388) 
Sal 
Eco RI (190) 
Eco RI (2322) 
I (989) 
Table 2.6: Restriction enzyme analysis of pMTNS3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11:  Confirmation of pMTNS3 plasmid by restriction enzyme digestion. A) The 
pMTNS3 plasmid map showing the position of the restriction enzyme digestion sites. B) 
Restriction enzyme digestion of pMTNS3 on an agarose gel. HR: Norgen’s HighRanger 
marker, Lanes numbered 1-4: pMTNS3 plasmid digested by restriction enzymes as 
shown in Table 2.6. The size of ladder bands is shown in bp.  
 
 
Lane Restriction enzyme 
Expected band  
size (bp) 
1 MfeI, AvrII 3721, 1346 
2 EcoRI, AvrII 2935, 1400, 732 
3 AccI, PstI 3236, 1831 
4 BamHI, SalI 4466, 601 
 la
dd
er
 m
ol
ec
ul
ar
 si
ze
 (b
p)
 
(A) 
(B) 
    L                 1                2                  3               4                L 
 
10000 
8000 
6000 
5000 
4000 
3000 
2500 
2000 
1500 
1000 
700 
500 
300 
 
77 
 
2.3.2.4- Cloning of HCV- E1 and NS3 under the CMV ie promoter 
Cloning E1 and NS3under the control of the CMV ie promoter is based on the 
plasmid pDC-CG, which contains the CMV ie promoter, in addition to a splicing donor/ 
acceptor signal and polyA signal from SV40. The newly formed plasmids were 
designated as pDCE1and pDCNS3. The plasmids were confirmed by restriction enzyme 
digestion and sequencing. The strategy for construction of pDCNS3 and pDCE1 is shown 
in Figure 2.12 and the restriction maps for both plasmids were shown in Figures 2.13 and 
2.14 respectively. The results show that pDCE1 and pDCNS3 were digested with several 
restriction enzymes and the observed bands are similar to what is expected from 
restriction analysis. Sequencing results showed no mutations in the constructs. 
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Figure 2.12: Schematic diagram showing the strategy for the construction of the 
pDCNS3 and PDCE1 plasmids. NS3 and E1 genes were digested from pMTNS3 and 
pMTE1 respectively, with AgeI and NotI. They were then cloned under the control of the 
CMV ie promoter and SV40 polyA signal in the pDC-CG plasmid after digestion with 
AgeI and NotI, releasing GFP. 
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Table 2.7: Restriction enzyme analysis of pDCNS3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13: Confirmation of pDCNS3 with restriction enzymes. A) pDCNS3 plasmid 
map showing the position of restriction enzyme recognition sites. B) Restriction enzyme 
digestion of pDCNS3 on an agarose gel. L: Norgen’s HighRanger ladder; Lanes 
numbered 1-4: plasmid DNA digested by restriction enzymes as shown in Table 2.7. The 
size of ladder bands is shown in bp. 
Lane Restriction 
enzymes 
Expected band 
size (bp) 
1 SalI 5335/811  
2 StuI 4568/1578  
3 KpnI/AvrII 5427/719  
4 AgeI/NotI 4233/1913  
(A) 
pDCNS3 
6146 bp
ITR
ITR
Ad
Frt
Pcmv 
 
SV40 
 
SV40 poly 
 
ns
 
Age I (1235)
Avr    II (1955) 
Kpn  I (1236) 
No I (3148)
Sa I (2556) 
Sa I (3367)
Stu  I (1285) 
Stu  I (2863) 
     L           1          2            3             4      
1500 
 
1000 
 
700 
 
500 
 
300 
 
10000 
8000 
6000 
5000 
4000 
3000 
2500 
2000 
    B 
 L
ad
de
r 
m
ol
ec
ul
ar
 si
ze
 (b
p)
 
80 
 
Table 2.8: Restriction enzyme analysis of pDCE1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14:  Confirmation of pDCE1 with restriction enzymes. (A) pDCE1 plasmid map 
showing the position of the restriction enzyme recognition sites. B) Agarose gel demonstrating 
the restriction enzyme digestion of pDCE1. First and last Lanes: Norgen HighRanger and 
PCRsizer markers respectively. Lanes 1-4: plasmid DNA digested by restriction enzymes as 
shown in Table 2.8. The size of ladder bands is shown in bp. 
Lane Restriction 
enzymes 
Expected band 
size (bp) 
1 AvaI 4795 / 242 bp 
2 MfeI 4771 / 266 bp 
3 KpnI/NheI 4849 / 188 bp 
4 EcoRI/NsiI 4161 / 876 bp 
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2.3.3- In-vitro evaluation of the expression of HCV-NS3 and E1 
2.3.3.1- Confirmation of the vaccines’ expression activity  
The expression of NS3 and E1 genes was confirmed in HEK 293 cells transfected 
with the constructed plasmids. The expression was determined using RT-PCR which 
indicates successful expression of both genes, NS3 (283 bp) (Figure 2.15) and E1 (448 
bp) (Figure 2.16) under the control of the three promoters CMV ie, MLP and E1A. These 
results confirmed the activity of the transcription of NS3 and E1 genes. 
 
 
 
 
 
Figure 2.15: Expression of NS3 24 h post-transfection in HEK 293 cells with different promoter 
plasmids, MLP (lane1),  E1A (lane 2) and CMV ie ( lane 3). PCR products of NS3 are shown 
(283 bp). L: Norgen’s FastRunner. Size of each ladder band is shown in bp. +ve is a positive 
control amplified from plasmid encoding NS3.  
 
 
 
 
 
 
 
Figure 2.16: Expression of E1 24 h post-transfection in HEK 293 cells with different promoter 
plasmids, MLP (lane 1), CMV ie (lane 2) and E1A (lane 3). PCR products of E1 are shown (448 
bp). L: Norgen’s FastRunner. Size of each ladder band is shown in bp. –ve is a negative control 
with no template, +ve is a positive control amplified from plasmid encoding E1.  
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2.3.3.2- Comparison of the transcription levels of HCV E1 and NS3 plasmids  
2.3.3.2.1- The transcription level of E1 driven by the different promoters  
The activity of three different promoters, CMV ie, E1A and MLP were compared 
in HEK 293 cells at different time points post-transfection, including 0, 12, 24 and 48 h. 
The expression levels for E1 were quantified using qRT-PCR. The E1 mRNA copy 
number was obtained using a standard curve of known plasmid concentration. The results 
show that the CMV ie promoter has the highest activity starting at 12 h, which increased 
at 24 h and reached a maximum at 48 h. At 12 h, both MLP and E1A demonstrated very 
low transcription levels, which increased to maximum activity at 24 h, then decreased 
slightly at 48 h. The mRNA copy number/ cell for CMV ie was significantly higher than 
for MLP and E1A at all points. The mRNA copy number/cell for E1A was higher than 
for MLP, but the difference was not significant (Figure 2.17). 
 
2.3.3.2.2- The transcription level of NS3 driven by the different promoters  
The transcription levels of NS3 were determined by qRT-PCR at different time 
points post-transfection of HEK 293 cells, including 0, 12, 24 and 48 h. The same trend 
was seen as that of E1. CMV ie demonstrated the highest transcription activity followed 
by E1A and then MLP. The mRNA level driven by CMV ie was higher than MLP and 
E1A promoters at all time points. Transcription level was low at 12 h and increased 
gradually over time at 24 h and 48 h. mRNA levels from both E1A and MLP reached a 
peak at 24 h and decreased at 48 h (Figure 2.18). 
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Figure 2.17: The level of E1 transcription under different promoters (E1A, MLP, CMV ie), over 
0, 12, 24, 48 h post-transfection in 293 cells. Copy numbers were obtained by qPCR using a 
standard curve of known plasmid DNA concentration. Graph (A) Comparison of the 3 promoters. 
Graph (B) Comparison of the 2 promoters E1A and MLP enlarged. Error bars represent the 
standard deviation. N=3. 
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Figure 2.18: The level of NS3 transcription under different promoters (E1A, MLp, CMV ie), 
over 0, 12, 24, 48 h post-transfection in 293 cells. Copy numbers were obtained by qPCR using a 
standard curve of known plasmid DNA concentration. Graph (A) Comparison of the 3 promoters. 
Graph (B) Comparison of the 2 promoters E1A and MLP enlarged. Error bars represent the 
standard deviation. N=3. 
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2.3.4- In vitro expression of E1 and NS3 proteins in E. coli 
2.3.4.1- Construction of bacterial expression plasmids pT7E1 and pT7NS3 
Recombinant E1 and NS3 proteins were expressed in E. coli in order to be used 
for the detection of E1 and NS3 antibodies induced by vaccination. First, NS3 and E1 
were cloned under the T7 promoter. The resultant plasmids,  pT7E1 and pT7NS3 (Figure 
2.19), were screened by AfeI enzyme digestion. The digestion showed the correct bands 
as expected (Figures 2.20, 2.21). The plasmids were then confirmed by sequencing.  
  
 
 
 
 
 
Figure 2.19: Schematic diagram showing the expression plasmids pT7E1 and pT7NS3 
 
 
 
 
 
 
 
Figure 2.20: Agarose gel showing the confirmation of pT7E1 plasmids with AfeI 
digestion. L: Norgen’s MidRanger. Size of ladder bands is shown in bp. The expected 
bands 3114 and 555 bp were obtained. 
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Figure 2.21: Agarose gel showing pT7NS3 plasmids confirmed with EcoR1 and SalI 
digestion. L: Norgen’s MidRanger. Sizes of the ladder bands are shown in bp. The 
expected bands 4524 and 596 bp were obtained. 
 
2.3.4.2- Expression and isolation of E1 and NS3 proteins 
The expression plasmids pT7E1 and pTNS3 were transformed into E. coli plysS. 
E1 and NS3 proteins were isolated from the inclusion bodies. The isolated proteins were 
separated by SDS-PAGE. The gel showed the expression of E1 protein (16.5 kDa; Figure 
2.22) and NS3 protein (68 kDa; Figure 2.23), with the correct bands but with minor 
bacterial protein contamination. The bacterial lysate from non-transformed E. coli plysS 
was loaded as a negative control. The control did not show the NS3 and E1 bands.  
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Figure 2.22: SDS-PAGE gel showing E1 (16.5 kDa) expressed and isolated from E.coli (Lanes 
2-5) compared to the non-transformed E.coli plysS (Lane 1) as a control (band of 16.5 kDa is 
absent). L: Norgen’s Proteoladders. The sizes of the ladder bands are shown in kDa. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23: SDS-PAGE showing NS3 (68 kDa) expressed and isolated from E. coli (Lane 3) 
compared to the non-transformed E. coli plysS (Lanes 1, 2) as a control (band of 68 kDa is 
absent).  L: Norgen Proteoladder 150.  The sizes of the ladder bands are shown in kDa.  
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2.3.5- The effect of different promoters on the efficacy of the vaccine 
2.3.5.1- Evaluation of HCV-E1 and NS3-specific antibody levels  
To investigate the effect of different promoters on the immune response, sera 
from immunized and control mice were collected 2 weeks after the last dose. The 
antibody level was measured using ELISA. All immunized animals produced antibodies 
against the HCV E1 and NS3 proteins. The specificity of the antibodies was confirmed 
by western blot. The results demonstrated high titers of HCV E1 and NS3-specific 
antibodies in animals injected with plasmids controlled by the CMV ie promoter. On the 
other hand, plasmids that contain Ad MLP and Ad E1AP resulted in lower antibody 
levels but were still higher than the control animals (Figures 2.24 and 2.25). The western 
blot confirmed the presence of E1 and NS3 antibodies shown by signal at the right band 
sizes. There were also extra cross reactive bands (Figures 2.26 and 2.27). 
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Figure 2.24: E1 antibody levels in the sera of animals immunized with E1 plasmids under 
different promoters: CMV ie (pCE1), MLP (pMTE1) and E1A (pEE1). The antibody levels were 
measured, 2 weeks after immunization, by OD at 450 nm in different serum dilutions using 
ELISA. Control animals were injected with PBS. Bars represent standard deviation, n = 3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.25: NS3 antibody levels in sera from animals immunized with NS3 plasmids under 
different promoters: CMV ie (pCNS3), MLP (pMNS3) and E1A (pENS3). The antibody levels 
were measured, 2 weeks after immunization, by OD at 450 nm in different serum dilutions using 
ELISA. Control animals were injected with PBS. Bars represent standard deviation, n = 3. 
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Figure 2.26: Western blot of mice groups immunized with E1 plasmids under different 
promoters: CMV ie (pE1), MLP (pME1) and E1A (pEE1) compared to non immunized mice. A 
band around 16 kDa showed the presence of E1 antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.27: Western blot of mice groups immunized with NS3 plasmids under different 
promoters: CMV ie (pCNS3), MLP (pMTNS3) and E1A (pENS3) compared to non immunized 
mice. A band around 70 kDa showed the presence of NS3 antibodies. 
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2.3.5.2- The effect of vaccination on serum miRNA levels  
Cellular miRNAs are essential in the regulation of all cellular activities and they 
determine the fate of several cell types. The purpose of this experiment was to investigate 
the relationship between the immune response and cellular miRNA. The levels of mir-
155, mir-181, mir-21, mir-196 and mir-296 were examined in animals immunized with 
E1 and NS3 plasmid vaccines. The results demonstrated an upregulation of certain 
miRNAs. mir-181 expression was upregulated in all immunized groups except the 
pCNS3 injected group, however the highest expression was observed in the groups 
immunized with pEE1. mir-21 was also upregulated in groups immunized with pMTNS3, 
pMTE1 and pEE1. Mir-296 showed a slightly elevated expression in those vaccinated 
groups that received pMTNS3 and pMTE1. However the increase in miRNAs was not 
statistically significant (p> 0.05). The results are shown in Figure 2.28. mir-155 and mir-
196 did not result in detectable Ct values (results not shown). 
 
 
 
  
 
  
 
Figure 2.28: The expression level of miRNAs 2 wks after mice immunization with E1 and NS3 
plasmids. The levels of mir-181, mir-21 and mir-296 in the sera of immunized animals are 
expressed as a relative change in fold compared to control animals (injected with saline) 
measured by ∆∆Ct method. Error bars represents standard deviations, (n=3). Results are 
considered significant if p value < 0.05.  
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2.4- Discussion 
 
DNA vaccination is a promising approach for challenging viruses. In addition to 
its ability to induce both cellular and humoral immunity, DNA vaccine technology allows 
plasmid modifications to enhance or broaden the immune response.  
However, DNA vaccine trials have shown limited immunogenicity in humans 
compared to small experimental animals. Therefore, optimization of the DNA vaccines is 
critical to enhance their efficacy. The focus of this thesis is to optimize antigen 
expression by using different promoters. Two promoters that were derived from 
adenovirus, the weak early promoter E1A and the strong late promoter MLP, were 
evaluated. These promoters were chosen in order to compare between early and late 
promoters and because they were not previously evaluated in DNA vaccine although they 
were evaluated for in vitro expression. 
  
2.4.1- In-vitro expression of HCV E1 and NS3 under different promoters 
Antigen expression under different promoters was evaluated in vitro. The results 
demonstrated a higher transcription level of NS3 and E1, driven by the CMV ie   
promoter compared to MLP and E1A promoters. This can be explained by the  known 
strength of the CMV ie promoter, due to the strong TATAA box, enhancers located 
upstream of the transcription initiation site, as well as its cyclic-AMP response elements 
(Boshart et al., 1985; Hunninghake et al., 1989). This result is consistent with other 
studies that compared different promoters and found that CMV ie was more effective in 
transgene expression (Zheng and Baum, 2005; Papagatsias et al., 2008). On the other 
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hand, both Ad promoters exhibited significantly lower transcriptional activity (mRNA 
level), which is in accordance with the results shown by Goossens et al., (2000), where 
they found that the CMV ie promoter induced 6-10 fold higher activity in reporter gene 
expression than MLP. Another experiment using adenovirus to express IL2 under MLP 
showed less expression than both RSV and CMV ie (Griscelli et al., 2003). In the case of 
the E1A promoter, it has been shown that its activity is 100 fold lower than the CMV ie 
promoter in neuronal cells (Smith et al., 2000). Moreover, Ad vectors induced expression 
of the E1A proteins under the CMV ie promoter 10 fold higher than its endogenous E1A 
promoter (Zheng et al., 2005).  
 The results showed that there was no significant difference between the activity 
of E1A and MLP, which coincides with the fact that the strong activity of MLP is related 
to late infection, resulting from the interaction of virus-induced transcription factors with 
the binding sites downstream to the promoter. This is confirmed by deletion of these sites 
which reduced transcription activity by 25-50 fold (Leong et al., 1990). It has been 
reported that Ad E1A protein supplied by HEK 293 cells can transactivate some 
promoters such as MLP and CMV ie (Cockett et al., 1990) and reduce the activity of the 
E1A promoter (Schaack et al., 2001). However our results showed that both E1A and 
MLP promoters have similar activity in HEK 293 cells, which agrees with the finding in 
natural infections that MLP demonstrates similar activity to the early promoters in the 
early phase (Nevins, 1981; Shaw and Ziff, 1980).  This indicates that HEK  293 cells can 
be used for monitoring Ad promoters’ activity, and the expression of E1 has minimal 
effects on their activity. 
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 In general, these results indicate that the CMV ie promoter is more effective in 
driving antigen expression. Although MLP is a strong promoter during viral infection, it 
is less effective when it is used alone.  E1A is a weak promoter, and therefore induced 
less activity. All promoters reached the maximum activity at 24 h as they need time for 
the accumulation of the mRNA to reach a detectable level. We did not monitor more 
points since we wanted to compare the activities of different promoters rather than the 
duration of their activity, however the mRNA level is expected to reduce gradually due to 
cell division and plasmid dilution. Even in animal immunization with plasmid vaccine, 
the antigen expression duration is not long enough so booster doses are usually needed. 
These lines of experiments demonstrated that weak but early promoters did not 
have an advantage over a strong promoter regardless if it is immediate, early or not. 
These results confirmed that the strength of the promoter is more important than temporal 
expression.   
2.4.2- Evaluation of the immune response against the vaccine constructs 
In order to investigate the correlation between the level of protein expression and 
humoral immune responses elicited by the HCV vaccine constructs, the development of 
E1 and NS3 antibodies in immunized mice was analyzed. The specificity of these 
antibodies was confirmed by western blotting. However some non-specific bands were 
observed indicating that some antibodies cross reacted with some E.coli proteins. The 
level of antibodies induced by each vaccine was compared and found that all constructs 
were capable of inducing a humoral response, however their efficacy was variable. The 
CMV ie promoter induced the highest antibody level, while the Ad promoters E1A and 
MLP exhibited lower and almost similar immune responses.  These results reflected the 
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activity of each promoter as seen in our in vitro expression results and confirmed the 
direct correlation between antigen expression and the immune response, lending further 
support to the accuracy of the in vitro results and choice of measure.  This relationship 
was also proven by Galvin et al. (2000). They demonstrated that HIV-1 Gag and Env 
antibody responses, which were induced by the CMV ie promoter, were higher than that 
of murine leukemia viral long terminal repeat promoters. They also showed that the 
higher antibody titer was related to the stronger promoter. The relation between the 
strong promoter and antibody titer is explained by the high antigen expression, which 
consequently enhances antigen presentation by APCs, and produces a potent immune 
response. Although Ad promoters were weaker than CMV ie, and exhibited lower antigen 
expression, they were still capable of inducing antibodies which could be further 
enhanced by using adjuvants. This may be useful in case of antigens that, if expressed in 
large amounts, would cause detrimental effects, such as the oncogenic E7 protein of 
Human papilloma virus (HPV) (Heck et al., 1992). In this study, other promoters were 
explored particularly, the effect of early and late promoters on the immune response were 
compared. It was anticipated that using immediate early promoters, even if they are weak, 
would induce a more rapid immune response and a higher titer of antibodies than strong 
but late promoters. However, the in vitro and in vivo results showed that the early 
promoter did not enhance the expression or the immune response.  This indicates that 
strong promoter like CMV ie is more effective in enhancing gene expressing and also 
vaccine immunogenicity. However, CMV ie has been used in DNA vaccine trials and 
could not induce optimal immunogenicity in humans. That underscores the need to 
explore more powerful approaches to enhance antigen expression. In addition, combining 
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a strong promoter with codon optimization or a potent adjuvant would optimize the 
efficacy of DNA vaccines.  Enhancing gene uptake is also important and could be 
realized by using different methods of delivery such as electroporation or gene gun 
technology that are more effective than i.m. injection and require a lower amount of 
DNA. 
Both antigens E1 and NS3 produce high levels of antibodies under the control of 
CMV ie, (Figures 2.24, 2.25), which indicates that they could be candidate vaccines that 
if given together, would maximize protection. However, this study was limited in that 
only one time point could be evaluated (2 weeks after the last dose). In future 
experiments the immune response can be monitored over longer periods to investigate the 
duration of the immune response and indicate the effectiveness of the vaccine. However, 
this vaccine with some more optimization would be expected to protect against 
heterologous strains of HCV due to the genetic conservation of E1 and NS3 among 
strains. However, the effect of DNA vaccine in small animals does not necessarily reflect 
the response in humans. Therefore, further exploration of these vaccines in large animals 
would be interesting to investigate their effectiveness for clinical trials. 
To conclude, the CMV ie promoter induced an enhanced immune response 
compared to the Ad promoters, indicating that a stronger promoter is more important for 
vaccine efficacy than an early promoter. However, since both Ad promoters induced 
significant level of antibodies, a small amount of DNA is enough to produce an immune 
response in small animals. That also suggests that any increase in the antigen expression 
even if small, could effectively enhance the immunogenicity of the DNA vaccine. 
97 
 
Therefore further exploration of different approaches to enhance antigen expression is 
warranted. 
 2.4.3- The serum miRNA levels in immunized animals 
miRNAs are small players that are involved in most cellular functions. 
Immunological functions, including immune cell maturation, differentiation and the 
ability to induce an immune response, are all controlled with a network of miRNA 
regulators. In this experiment, the relationship between miRNAs and the immune 
response was investigated by monitoring the change in serum miRNA levels after 
immunization. Certain miRNAs that are involved in immune system regulation were 
tested.  It has been observed, in Figure 2.28, that mir-181 is up-regulated in all 
immunized animals compared to the controls, except for one group which was injected 
with the plasmid pCNS3. mir-21 and mir-296 were up-regulated only in some groups. 
However these changes were not statistically significant. Connecting these results to the 
roles of these miRNAs indicates that they are implicated in the regulation of the immune 
response and also can be indicators for detection of the immune response after 
vaccination. miRNAs were shown to be regulated through TLR stimulation and 
activation of the transcription factor nuclear factor-kappa B (NF-κB) pathway. In the case 
of plasmid DNA, the CpG motifs in the plasmid backbone stimulate the TLR-9 and 
induce a cascade of pro-inflammatory cytokines that is expected to up-regulate mir-21, 
mir-181 and mir-196 (Moschos et al., 2007; Sonkoly et al., 2008, Marquez et al., 2010).  
mir-21 has a key role in negative regulation of TLR-dependent inflammatory 
cytokines to reduce their harmful effect on the host (Sheedy et al., 2010). Others reported 
that mir-21 activates NF-κB increasing the inflammatory response (Shin et al., 2011). 
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Up-regulation of mir-21 in this experiment indicates the activation of the immune system 
after vaccination by CpG motifs in the plasmid vaccines which are known to activate 
other pro-inflammatory cytokines. Therefore, whether it acts as a positive or negative 
regulator of NF-κB, mir-21 appears to be involved in immune response regulation and the 
increase in its expression reflects the stimulation of cytokines after vaccination.  
mir-181 is involved in the activation of B-cells (Chen et al; 2004; Shivdasani, 
2006) and T-cells, as well as the increase in T cell receptor (TCR) expression. The up-
regulation of mir-181 in some vaccinated groups suggests it is vital to the activation of 
the immune response and may be one of the mechanisms by which DNA vaccine induces 
its effect. Mir-296 has an antiviral effect and has been shown to inhibit viral replication. 
Induction of mir-296 by plasmid vaccines is stimulated by IFN-B induced through CpG 
dependent stimulation of TLR. This confirms that DNA vaccines can have a therapeutic 
effect not only by priming the immune response but also by induction of anti-HCV 
miRNAs including mir-196, mir-296, mir-351, mir-431 and mir-448, all of which are 
induced by IFN-B and inhibit HCV replication (Pedersen et al., 2007).    
 The variation in the level of the miRNA expression in the vaccinated groups may 
be a result of the variable number of CpG motifs in different plasmid backbones.  
Moreover, the expression level does not reflect the antibody level in the different groups, 
which shows that the immune response is regulated by a complex network of miRNA and 
other factors. Besides, the miRNAs regulate the immune response in a nonspecific 
manner via activation of the innate response, while the specific activation of the adaptive 
immunity by the antigen still plays a major part.  Also the variation in miRNAs levels in 
different animals before immunization might have an impact. Therefore, pre-
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immunization sera collection to compare the level of miRNA before and after the 
vaccination would give more accurate results. Since the changes miRNAs under test were 
not significant, optimization of the CpG motif content in the DNA vaccine may enhance 
miRNA expression and hence increase immunogenicity. 
In general this study showed that miRNAs are possibly involved in the immune 
response, suggesting that stimulation of certain miRNAs or co-delivery with a DNA 
vaccine could enhance the immunogenicity of the vaccine.  
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2.5- Conclusion 
 
In this study the effect of promoters on the efficacy of DNA vaccines against 
HCV were evaluated. Plasmids were constructed encoding HCV antigens NS3 and E1 
under different promoters. A weak early promoter (E1Ap) and a strong late promoter 
(MLP) derived from adenovirus, were compared to the standard strong early promoter 
CMV ie.   The effects of these promoters were evaluated based on antibody titers and 
miRNA expression profile.  Based on data reported in this chapter, it is concluded that:  
1- The in vitro expression by CMV ie is much stronger than Ad promoters.  
2- The E1A and Ad MLP promoters showed similar expression pattern in small 
animals. It would be interesting to see the expression pattern in larger 
primates.  
3- CMV ie induced a higher antibody level after vaccination, indicating that 
strong early promoters are required for maximum performance of a DNA 
vaccine. 
4- Measuring miRNAs levels, induced after vaccination, showed that plasmid 
DNA stimulates miRNA induction. Although not in a significant level, these 
results merit further investigation into the relationship between vaccine CpG 
content and miRNA level.   
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Chapter 3 
EVALUATION OF ADENOVIRUS AS A RECOMBINANT VACCINE 
AGAINST HCV 
 
3.1- Introduction 
HCV causes a chronic infection in more than 170 million people in different areas 
of the world. The persistence of the virus is due to an ineffective host immune response. 
However, it was found that 15% of patients were able to clear the infection in 6 months. 
Spontaneous viral clearance is related to a potent cellular immune response, which can 
eliminate the infected cells and completely resolve the virus (Takaki et al., 2000; 
Vertuani et al., 2002). This finding emphasizes the importance of vaccination as a 
therapeutic and preventative tool. The DNA vaccine strategy is promising but it shows 
some limitations in clinical trials. One major factor is limited antigen uptake and amount 
expressed in host cells after plasmid DNA injection (Manoj et al., 2004). Similar to the 
DNA vaccine, recombinant viral vectors express the antigen intracellularly and stimulate 
both the humoral and cellular immune response. However, recombinant viral vectors are 
more effective in infecting the cell and delivering the antigen encoding gene to the 
nucleus. Moreover, viral vectors enhance the immunogenicity of the vaccine via 
stimulation of TLR-dependent innate immunity (Zhu et al., 2007). Human Ads have 
proven to be effective vectors for delivery and expression (Haj-Ahmad and Graham, 
1986; Morin et al., 1987; Schneider et al., 1989) and they have number of advantages. 
First, they are well characterized and easy to manipulate. Second, they can be grown to 
high titer. Third, Ad can package 105% of its genome size into its capsid, 
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accommodating up to 1.8 kb of foreign DNA (Bett et al., 1993). Replication defective Ad 
vector with E1 and E3 deletions can accommodate a larger insert of around 7.5 kb (Xiang 
et al., 1996; Makimura et al., 1996). Ad vector vaccines have induced potent neutralizing 
antibodies and potent CD8+ T cell response against several pathogens including rabies 
(Xiang et al., 1996) and HIV (Shiver et al., 2002) and HCV (Arribillaga et al., 2002). 
Cells infected with Ad vectors live for 7-10 days before they are cleared by CTL in mice. 
This allows for long-lasting antigen presentation (Yang et al., 1994).  
Ad activates the innate immune system through several pathways. Viral DNA 
stimulates the cellular TLR2 and TLR9 receptors in the endosome (Yamaguchi et al., 
2007; Appledorn et al., 2008) and in the cytoplasm via NALT3, a Nucleotide 
Oligomerization Domain (NOD)-like receptor family member (Muruve et al., 2008). Ad 
signaling results in the activation of the IFN pathway, and secretion of pro-inflammatory 
cytokines such as IL-6, IL-12, IFN and tumor necrosis factor-α (TNF-α) (Zhang et al., 
2001). Ad vaccine also causes DC maturation (Molinier-Frenkel et al., 2003; Philpott et 
al., 2004), and initiates adaptive immunity against the transgene and Ad genes. The main 
problem with the Ad vaccine is pre-existing immunity against the virus. Repeated 
administration of the same viral vector greatly reduces the immune response.  
  In this study, Ad was evaluated as a vaccine vehicle against HCV. To achieve 
this purpose, a recombinant Ad vector encoding the NS3 gene (rAdNS3) was constructed 
and the efficacy of the vaccine was evaluated by measuring the NS3 antibody levels in 
immunized animals. In addition, the levels of specific miRNAs including mir-181, mir-21 
and mir-296 were evaluated in the sera of immunized mice. These miRNAs are involved 
in immune response regulation. 
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3.2- Methods 
3.2.1- Cell culture 
Human embryonic kidney (HEK) 293 cells (Graham et al., 1977; Microbix Inc., 
ATCC CRL-1573) were used for the construction of the adenovirus vectors. The cells 
were maintained in MEM (Invitrogen) supplemented with 10% (v/v) FBS (Hyclone), 1% 
(v/v) Antibiotic-Antimycotic (10,000 units/mL penicillin G sodium, 10,000 μg/mL 
streptomycin sulfate and 25 μg/mL amphotericin B; (Invitrogen Corp., Gibco), 1% 
GLUTAMAXTM-1 (Invitrogen Corp., Gibco), 3% (v/v) sodium bicarbonate (Invitrogen 
Corp., Gibco), at 37° C in 5% CO2. Cells containing the virus were grown in complete 
MEM supplemented with 5% FBS. The HEK 293 cells were passaged every 3 days at a 
split ratio of 1:2 after treatment with saline citrate (15 mM sodium citrate, 135 mM 
potassium chloride).  
HeLa cells (ATCC) were used in the evaluation of adenovirus activity. They were 
maintained similarly to HEK 293 cells, except for the serum used and the cell lifting step. 
The MEM media was supplemented with 10% Donor Horse Serum (DHS) (PAA 
Laboratories Inc.) and the cells were detached using 0.25% trypsin (Invitrogen Corp., 
Gibco) in 4 mL of versene (for 1 L: 1.0g glucose, 0.4g KCl, 8.0g NaCl, 0.58g NaHCO3 
and 0.2g EDTA). The HeLa cells were split at a ratio of 1:3. 
 
3.2.2- Adenoviral culture 
3.2.2.1- Adenovirus generation 
Recombinant adenovirus vectors encoding the NS3 gene were constructed based 
on the AdMax (Microbix) Ad vector system (Ng et al., 1999). This method was based on 
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homologous recombination between a shuttle vector including the NS3 transcription 
cassette and Ad vector plasmid. The shuttle plasmid was a modified version of the 
pDC511 plasmid (Microbix) constructed by inserting an antigen transcription cassette 
into the plasmid.  The shuttle plasmid contains the left end and right end of the Ad5 
genome.  It also contains an Frt site, which is essential for FLP (a yeast recombinase)-
mediated site-specific recombination. The construction of the shuttle vector pDCNS3 was 
previously shown in Figure 2.12. The Ad vector pBHGfrtΔE1E3FLP contains almost all 
of the Ad5 genome except for two deletions: E1 and E3 regions. In addition, it contains 
an FLP gene cassette that expresses the recombinase FLP. This recombinase mediates 
site-specific recombination at the Frt site. The two plasmids were co-transfected into 
HEK 293 cells, which produce the E1 protein necessary for viral packaging. The co-
transfection was carried out in a 6-well plate. For each well, an aliquot of transfection 
mixture, containing 5 µL lipofectamine 2000 (Invitrogen) and 2.5 µg from each plasmid 
in 500 µL Opti-MEM medium (Invitrogen), was used. Once inside the host cell, 
homologous recombination occurs at the homologous regions shared by the shuttle and 
genomic plasmid, thus the transgene cassette transferred into the Ad vector. After 10-15 
d, the cells were examined for typical adenovirus cytopathic effect (CPE). The resultant 
viruses are capable of infecting the experimental host cells, but are replication defective 
due to the absence of the E1 region. The schematic representation of rescuing the virus is 
illustrated in Figure 3.1. 
3.2.2.2- Viral DNA extraction and confirmation 
When the cells in the monolayer displayed complete CPE (i.e, become rounded 
but still attached to the plate), the medium was collected and stored at -70° C after adding 
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sterile glycerol to a final concentration of 10% v/v. This medium contained released 
viruses that could be used for preliminary experiments. The infected cells, which 
remained attached to the surface of the plate, were lysed to extract viral DNA using a 
modification of the Hirt extraction method (Hirt, 1967). Briefly, 500μL of lysis solution 
(10 mM Tris-HCl, 100 mM EDTA, 0.4% (w/v) SDS, 0.5 mg/mL pronase) was added to 
the attached cells and the plate was incubated at 37° C for 4-10 h. The lysate was loaded 
on a Norgen DNA isolation column to recover the viral DNA.  Confirmation of the viral 
DNA was done by restriction enzyme digestion with HindIII and gel electrophoresis. 
 
3.2.2.3- High titer adenovirus production  
The medium collected from the initial stock was used to infect more HEK 293 
cells on 100 mm plates. Two millilitres of virus medium was diluted in a total volume of 
8 mL PBS++ infection medium (0.01% CaCl2.2H2O and 0.01% MgCl2.6H2O dissolved in 
PBS). The medium was aspirated from HEK 293 cells, and the infection medium was 
added and incubated for 1 h at 37○ C and 5% CO2. Complete growth medium was added 
to 20 mL, and incubated. A total of 15 plates of HEK 293 cells with 90% confluence 
were infected. When the cells displayed complete CPE, the cells were scraped with a 
rubber policeman. The medium and cells were collected in a 50 cc centrifuge tube and 
centrifuged at 1000 x g for 5 min. The supernatant was collected and stored at -70○ C. 
The cell pellet was subjected to three rounds of freezing and thawing to release the virus. 
The crude virus stock was supplemented with 10% sterile glycerol and stored at -70○ C.  
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3.2.2.4- CsCl purification and concentration of Adenovirus 
For each 150 mm plate, the medium containing infected cells was collected and 
centrifuged. The cell pellet was suspended in 1 mL 15 mM Tris, pH 8. The cell 
suspension was subjected to 4-5 rounds of freezing and thawing to lyse the cells and 
release the virus. The cell debris was removed by centrifugation at 2000 x g for 5 min. 
For every 3.2 mL of cell-viral suspension, 1.8 mL of saturated cesium chloride dissolved 
in 15 mM Tris buffer was added, resulting in a density of 1.35 g/mL. This mixture was 
aliquoted into the appropriate Beckman ultracentrifuge tubes with a rubber seal lid, and 
centrifuged at in a type 70.1 Ti rotor in a Beckman L8-80M ultracentrifuge at 246,960 x g 
for 22 h at 22°C. The viral particles then appeared as a single band in the middle of the 
tube.  The viral band was collected using a syringe with 21 gauge needle after puncturing 
the tube slightly above the band. The viral bands were pooled in a final volume of 1.5 
mL. To get rid of Cscl, the virus stock was dialyzed at 4° C against two changes of 4 L 
PBS buffer, with a pH of 7.4. The virus was stored at -70° C after adding sterile glycerol 
to a final concentration of 10%. 
 
3.2.2.5- Adenovirus titration 
Adenovirus titration was performed either by RT-qPCR or by measuring the 
absorbance at 260 nm to determine the number of particles per mL. One A260 unit (one 
O.D. unit) is equivalent to ~1012 viral particles (VP)/mL (Maizel et al., 1968). To 
determine the PFU/mL, a plaque assay was used. 
The plaque assay was carried out by infecting HEK 293 cells with serial dilutions 
of the virus.  HEK 293 cells were grown in 6-well plates until 80-90% confluent.  Ten-
fold dilutions of a viral stock were prepared in 1 mL PBS++. The medium was aspirated, 
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and a 0.5 mL aliquot of each dilution was added to the cell monolayer in each well, in 
duplicate. The plate was incubated for 1 h allowing for viral attachment to the cells. The 
cells in each well were overlaid with a 6 mL mixture of equal volumes of 1% melted 
agarose solution with 2 x MEM medium, and incubated at 44○ C. The overlay was 
allowed to solidify for 15 min at room temperature before returning the plate to the 
incubator. The plaques were counted 5-7 d post-infection from dishes bearing 
approximately 20 to 80 plaques. The viral concentration was determined in PFU/mL as 
follows: titer = (number of plaques)(dilution factor)/(infection volume). 
For isolation of recombinant viruses by plaque purification, well isolated plaques 
were picked around 5 d post-infection. The plaque-purified vectors were used as 
inoculum for the preparation of the high-titer viral stocks described previously. 
 
3.2.2.6- Adenovirus infection 
Ad infection of mammalian cells was carried out in 6-well plates using a volume 
of the viral stock equivalent to the desired multiplicity of infection (MOI). This viral 
volume was mixed with PBS++ in a total volume of 500 µL/ well, and was then added to 
the cell monolayer (after aspirating the medium). The 6-well plate was then incubated for 
1 h at 37º C with 96% relative humidity and 5% CO2. The plate was swirled every 15 
min. Subsequently, 2 mL of the culture medium was added to each well, and the plate 
was incubated for 24 h. 
 
3.2.3- In vitro evaluation of adenoviral transcription activity 
rAdNS3 mRNA was quantified using qRT-PCR as explained earlier in Chapter 2.  
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3.2.4- Animals and immunization protocol 
Female BALB/c mice aged 6-8 weeks old (18-20 g of weight) were purchased 
from Charles River Breeding Laboratories, and housed at the animal care facilities of 
Brock University. All animal work was approved by the Brock University ACC, and 
done according to CCAC guidelines required for experimentation with animals. Three 
animals were used for each group. Immunizations with rAdNS3 were accomplished by 
inoculating 1×107 PFU in 100 µL of PBS, into the TA muscle bilaterally. Animals were 
given only one dose. The control group was injected with PBS. Mice were anaesthetized 
by inhalation of 5% isoflurane with oxygen prior to injection.  
 
3.2.5- Blood collection and serum preparation 
Blood samples were collected by heart puncture 6 wk after immunization. The 
blood was incubated in an upright position at room temperature for 30-45 min to allow 
for clotting, and then centrifuged at 4º C for 15 min at 7000 x g. The serum (supernatant) 
was collected, and small aliquots were stored at -80º C. 
 
3.2.6- Immunological analysis 
 
3.2.6.1- Enzyme-Linked Immunosorbent Assay (ELISA) 
 
ELISA was used to monitor the levels of NS3-specific antibodies in the sera 
collected from immunized animals. ELISA Immulon 4HBX plates (96-well) (VWR 
International, LLC) were coated with recombinant NS3 (expressed in E.coli) at 0.1 
µg/well in a bicarbonate buffer (50 mM NaHCO3 buffer, pH 9.6) overnight at 4º C. The 
plate was washed 5 times with wash solution (PBS + 0.1% Tween 20). The active sites 
on the plates were blocked with wash solution containing 2% BSA for 2 h at room 
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temperature to block non-specific antibody binding. The plate was washed again and 
two-fold serial dilutions of murine sera (in PBS containing 1% BSA) were added to each 
well, and incubated for 2 h at room temperature on an orbital shaker. To determine IgG 
levels, 100 µL of peroxidase-conjugated goat anti-mouse IgG antibody (Sigma), at a 
dilution of 1:5000, was added to each well. The reactions were initiated by adding OPD 
substrate (Sigma) at 200 µL/well followed by 30 minute incubation at room temperature. 
The OD was measured at 450 nm by a thermo scientific ELISA reader. OD values had to 
be at least twice as high as the control values from non- immunized animals to be 
considered positive. 
 
3.2.6.2- Western blot 
Western blots were performed using standard protocols. Briefly, the proteins were 
separated on a 12% SDS-polyacrylamide gel followed by electrophoretic transfer to a 
polyvinylidene difluoride (PVDF) membrane (Pall Sciences). The membrane was soaked 
in methanol, followed by soaking in 1X Blotting Buffer (along with the blotting paper 
and the SDS-PAGE gel containing the protein).  The transfer unit was then assembled 
according to the manufacturer’s instructions, and the proteins were transferred to the 
PVDF membrane at 40 mA per gel for 1 h.  The PVDF was then blocked overnight using 
5% Skim Milk 1X TBST (8.8 g of NaCl, 0.2 g of KCl, 3g of Tris base and 500μL of 
Tween-20 / L, pH 7.4) and incubated with pooled sera from each injected animal group 
(1:1000 dilution in 0.5% skim milk). The PVDF membrane was then washed three times 
with 1X TBST, and reacted with 1/5000 dilution of HRP-conjugated anti-mouse IgG 
(Sigma). After three washing steps, the membrane was developed by chemiluminescent 
detection using a Pierce CN/DAB Kit (Thermo Fisher Scientific).      
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3.2.6.3-miRNA quantification 
Specific miRNAs involved in the regulation of the immune response were 
quantified in the serum of immunized and control mice using qRT-PCR according to the 
standard technique described in Chapter 2 with some modifications. First, total RNA was 
isolated from 100 µL serum using the Total RNA Purification Kit (Norgen Biotek Corp.) 
according to the manufacturer’s instructions. A 20 µL RT reaction was performed using a 
0.5 µL (50 mM stock) stem loop primer specific to each miRNA and 200 ng of RNA.   
Real-time PCR was performed on the cDNA using specific forward primers for 
each miRNA and one universal reverse primer. For relative quantification of miRNA 
levels, the Ct values were normalized to the 5SrRNA gene. The expression levels of 
miRNAs were indicated as fold-difference in expression compared to the non-immunized 
animals.  The fold change values were calculated with the ΔΔCt method. Primers used 
are shown in Table 2.2 (Chapter 2). 
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3.3-Results 
 
3.3.1- Confirmation of adenovirus encoding HCV-NS3 (rAdNS3) 
 Adenovirus encoding HCV-NS3 was rescued by homologous recombination 
between the shuttle plasmid pDCNS3 encoding NS3 under the CMV ie promoter and the 
genomic adenovirus plasmid pBHGfrtΔE1E3FLP. The resultant virus was designated 
rAdNS3. To confirm recovery of the appropriate costruct, viral DNA was isolated from 
the infected HEK 293 cells and digested with HindIII. Figure 3.1 illustrates the 
construction of rAdNS3 virus and Figure 3.2 shows the restriction digestion confirmation 
of rAdNS3 and the expected bands compared to the wild type Ad5. The viral DNA bands 
appear on a smear background of cellular DNA. 
The construct was also confirmed by PCR using two primers, the first primer, for 
Ad E1 region (AdE1), was used to check for possible contamination by wild type Ad5 
that may have developed by homologous recombination with the E1 available in HEK 
293 cells. The DNA isolated from infected HEK 293 cells was used as the template. 
Since the constructed virus has an E1 deletion, the viral DNA showed no amplification. 
Plasmid DNA containing E1 was used as a positive control. The second primer, the NS3 
primer, gave a PCR product of 283 bp as expected for NS3 amplicon, which confirmed 
the presence of the NS3 gene in the virus. Figure 3.3 shows the PCR product of both 
primers. After confirmation, the virus was purified by cesium chloride banding and 
titrated by plaque assay.  
 
 
 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Schematic diagram representing the construction of the recombinant 
adenovirus (rAdNS3) through a homologous recombination system in HEK 293 cells. 
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Table 3.1: Restriction enzyme analysis of rAdNS3 digested by HindIII compared to the 
wild type adenovirus. The fragment sizes underlined indicate the bands that are different 
from Ad5 and specific to rAdNS3. 
 
HindIII digestion Wild type Ad5 rAdNS3 
Fragments (bp) 
8010 
5665 
5324 
4597 
3437 
2937 
2804 
2081 
1008 
75 
8010   
6121 
5322 
4597 
3012 
2937 
2081 
1004 
75 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Confirmation of rAdNS3 by restriction enzyme digestion. The agarose gel shows the 
confirmation of rAdNS3 by HindIII digestion. L is the Norgen’s UltraRanger ladder. The size of 
ladder bands is shown in bp. 
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Figure 3.3:  Confirmation of rAdNS3 by PCR using DNA isolated from rAdNS3 
infected HEK 293 cells. The agarose gel shows amplification using two different primers, 
Ad-E1 primer: lane 1 (-ve control), lane 2 (+ve control from plasmid encoding E1 
produced E1 fragment of 867 bp), lane 3 (rAdNS3 DNA template produced no 
amplification), and HCV-NS3 primers: lane 4 and 5 (rAdNS3 template produced NS3 
band of 396 bp). Lane 6 (-ve control). The first and last lanes are Norgen’s FastRunner 
DNA Ladder. The sizes of ladder bands are shown in bp.   
 
3.3.2- In-vitro evaluation of NS3 expression  
3.3.2.1- Confirmation of the vaccine’s expression activity 
The expression activity of the recombinant Ad was confirmed in HeLa cells 
infected with rAdNS3 at MOI of 5 PFU. The transcription of NS3 was confirmed by RT-
PCR   24 h after infection. Figure 3.4 shows the NS3 PCR product with the expected size 
(396 bp), confirming transcription of the NS3 gene. 
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Figure 3.4: Transcription of NS3 mRNA 24 h post-infection of rAdNS3 in HeLa cells. C:  the -
ve control (no template). rAdNS3: RNA template from infected HeLa cells showed RT-PCR 
amplification product of NS3 (396 bp). L is the Norgen’s FastRunner ladder. The sizes of ladder 
bands are shown on the right side in bp.  
 
3.3.2.2- Transcription level of HCV- NS3 from adenoviral vectors  
 HeLa cells were infected with the recombinant adenoviruses rAdNS3 at an MOI 
of 5. The transcription level of NS3 was evaluated by qRT-PCR at 0, 12, 24 and 48 h 
after infection. The results showed that adenovirus successfully drove high expression of 
NS3, represented by high mRNA levels. The mRNA level increased early, at 12 h, and 
increased at 24 h. It then slightly decreased at 48 h (Figure 3.5). 
 
 
 
 
 
 
 
Figure 3.5: The transcription level of NS3 in HeLa cells infected with rAdNS3 over 0, 12, 24, 
48h post-infection. Copy numbers were obtained by qPCR using a standard curve of known 
plasmid DNA concentration. Error bars represents the standard deviation, n=3. 
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3.3.3- Evaluation of HCV NS3 specific antibody levels in immunized animals 
 An ELISA was performed to evaluate the antibody against NS3, expressed by the 
Ad vector, compared to the control animals injected with PBS. The animals showed a 
high titer of NS3 antibodies six wks after immunization (Figure 3.6). This was higher 
than antibody level induced 2 weeks after the last boost in the animals injected with the 
NS3 plasmid vaccine driven with the same promoter (CMV ie) as in the virus (Figure 
3.7). The specificity of NS3 antibodies was confirmed by western blot giving signal at the 
right band size. There were also extra cross reactive bands (Figure 3.8). 
 
 
 
 
 
 
 
 
 
Figure 3.6: NS3 antibody levels induced by the rAdNS3 vaccine 6 weeks after immunization. 
The antibody levels were measured by OD at 450 nm in different serum dilutions using ELISA. 
Control animals were injected with PBS. Bars represent the standard deviation, n = 3. 
 
 
 
 
 
 
Figure 3.7: Comparison of NS3 antibody levels induced by plasmid (pCNS3) and viral (rAdNS3) 
vectors. The antibody levels were measured by OD at 450 nm in different serum dilutions using 
ELISA. Control animals were injected with PBS. Bars represent the standard deviation, n=3. 
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Figure 3.8: Western blot of mice groups immunized with rAdNS3 and pCNS3 compared to non 
immunized mice. A band around 70 kDa showed the presence of NS3 antibodies. 
 
3.3.4- The miRNA level in serum after rAdNS3 immunization  
To assess the relationship between the response elicited by immunization and 
miRNA level, sera were collected from animals injected with pCNS3 and rAdNS3, as 
well as the control animals (one control had no injection, while the other control was 
injected with Ad5). qRT-PCR was performed to compare the level of mir-181, mir-21 
and mir-296 in all groups. The CT values were normalized to the 5SrRNA gene. Using T- 
test, the results showed a significant upregulation of mir-181 and mir-21 in animals 
injected with rAdNS3 and Ad5 (p < 0.05). Mir-296 showed higher expression only in 
animals injected with Ad5 however it was not statistically significant (p > 0.05). pCNS3 
showed non-significant change as compared to non-immunized control animals (p > 
0.05). The results are shown in Figure 3.9. 
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Figure 3.9: The expression levels of microRNAs in the sera of mice immunized with rAdNS3 
and pCNS3. The level of mir-181, mir-21 and mir-296 are expressed as a change in fold 
compared to the levels found in the sera of the control animals (injected with saline) measured by 
ΔΔCt method. Error bars represent thestandard deviations. n=3. Result is considered significant 
(*) if p value < 0.05. 
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3.4- Discussion 
 
HCV clearance requires a potent immune response, including specific antibodies 
and cytotoxic T cells. Recombinant viral vaccines are an attractive approach to induce 
strong humoral and cellular immune responses, since both are critical factors against viral 
infection. Clinical trials have shown that antigen uptake and level of expression are 
critical factors affecting the efficiency of the vaccine (Manoj et al., 2004). Since antigen 
expression level correlates with efficient antigen delivery, the delivery vehicle is 
important in protecting the DNA and enhancing delivery, thus increasing the amount 
available for expression. Recombinant viral vectors are more efficient in the entry to the 
host cell via receptor attachment and deliver the DNA to the nucleus more efficiently, 
being protected by the protein capsid (Miazawa et al., 1999). Therefore, viral vectors are 
good candidates for vaccine delivery. Particularly, Ad is known for its efficient 
transduction for most types of cells, including APCs, and its high transgene expression 
capacity.  
In this study, an HCV vaccine was constructed based on an Ad vector encoding 
NS3 (rAdNS3). The Ad vector was evaluated for in vitro expression and in vivo induction 
of immune response. Results revealed a high level of NS3 transcription in HeLa cells, as 
evidenced by the NS3 mRNA level. The mRNA level became detectable at 12 h post-
infection and increased with time. We did not test earlier points, however Ad has been 
shown to express the early genes just 4 h post-infection (Shaw and Ziff, 1982). The high 
level of NS3 mRNA indicates highly efficient cell infection by the Ad vector. In addition, 
NS3 was cloned under the control of the potent early CMV ie promoter that provides a 
high transcription level (Candolfi et al., 2006). 
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3.4.1- The immune response against rAdNS3 immunization 
To evaluate the activity of rAdNS3 vaccine in vivo, mice were immunized with 
rAdNS3 and compared the NS3 antibody level to the plasmid vaccine pCNS3 (Chapter 
2). The rAdNS3 vaccine was given in a single dose, as the adenovirus proteins would 
induce neutralizing antibodies that would inhibit the infection of any subsequent dose, 
resulting in a decreased immune response (Capone et al., 2006). However, the DNA 
vaccine requires boosting doses due to the inefficient uptake by APCs. The results 
showed that rAdNS3 induced higher antibody levels six wks after a single injection, than 
that elicited two wks after the third boost of pCNS3 (Figure 3.7). Since NS3 transcription 
is driven with the same promoter (CMV ie) in both vectors, the increase in the immune 
response is most likely due to the delivery system. This outcome reflects a strong and 
prolonged immune response elicited by Ad vectors. This response may be driven by 
various mechanisms including efficient cell transduction, high level antigen expression, 
and the adjuvant effect of other Ad proteins. These results confirmed the importance of 
efficient antigen delivery to induce a strong immune response and the advantages of Ad 
as a vaccine vector. The results are consistent with another report by Arribillaga et al. 
(2002). They showed a potent immune response elicited 10 days after intrapretoneal 
injection (i.p.) of 109 PFU of Adenoviral vector encoding NS3. In the current study, 
lower dose was used for i.m. injection (107 PFU) and immune response was shown for 
longer peiod (6 wks). Our results indicate that i.m. injection may be more effective than 
i.p.  injection. Prolonged and strong immune responses were also shown by Adenovirus 
encoding NS3 fused to MHC-II (Mikkelsen et al., 2011). 
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Since HCV chronicity is caused by a low, ineffective immune response (Thimme 
et al., 2002),  rAdNS3 may be a good candidate as a prophylactic and therapeutic vaccine 
based on its efficient prolonged immune response. This vaccine warrants further 
investigation in large animals. Ad vector was tested only with NS3 antigen. However, as 
shown in Chapter 2, E1 produced a high level of E1 antibodies. Therefore, including E1 
antigen in the same Ad vector would be expected to broaden the immune response, 
inducing neutralizing antibodies and cellular immunity.  
3.4.2- The Effect of rAdNS3 vaccination on miRNA expression 
To investigate rAdNS3 vaccine activity, and the mechanism of activating innate 
immunity, the level of selected miRNAs was evaluated in the serum of the immunized 
animals to monitor any changes compared to control animals. mir-181 and mir-21 were 
chosen for their role in immune cell differentiation and immune response regulation. 
Other miRNAs which target the HCV genome and are induced by IFN-β, such as mir-
296, were also selected (Pedersen, et al., 2007). Comparing the miRNA levels in groups 
injected with rAdNS3 and pCNS3 to the control animals (Figure 3.9), showed that the 
animals immunized with rAdNS3 exhibited significantly higher levels of mir-181 and 
mir-21 than animals injected with pCNS3 and the control animals, while mir-296 did not 
change with either vector. Since pCNS3 did not induce significant changes in mir-181 
and mir-21 levels compared to the control, it is suggested that the change is due to the Ad 
vector elements rather than the antigen. The higher level of miRNA induced by an Ad 
vaccine seems to be correlated to the efficient antigen delivery and activation of the 
innate immune system. miRNAs are induced through TLR activation by dsDNA, as is the 
case for Ad vectors. These results are in accordance with the finding that miRNAs are 
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upregulated with viral stimuli through TLR and inflammatory cytokines such as IFN 
(Sonkoly et al., 2008).  miRNA upregulation does not seem to be related to the antigen, 
but to the vector itself. To verify this idea, the miRNA level was compared in animals 
injected with either rAdNS3 or wild type Ad5 that contains the full adenovirus genome 
and no antigen insert. Surprisingly, Ad5 was found to induce lower levels of mir-181 and 
mir-21, and higher levels of mir-296. These observations could be explained by the 
presence of the E1 and E3 genes in the wild type (Ad5). E1 and E3 are known to subvert 
the innate immune system, and inhibit the cytokine induction pathways (Russell, 2000; 
Horwitz, 2001). This is expected to subsequently downregulate mir-181 and mir-21. On 
the other hand, mir-296 levels were upregulated with Ad5, which is related to the 
transformation induced by the E1 region. These results indicate that the differential 
expression of miRNAs is related to Ad vector (rAdNS3) lacking E1 and E3, and those 
miRNAs are related to the immune response activation. mir-181, reported to be localized 
in B-lymphocytes, has been implicated in the regulation of the maturation, proliferation, 
differentiation, and activation of immune cells (Chen et al., 2004; Neilson et al., 2007; 
Tsitsiou and Lindsay 2009). It also regulates T-cell receptor signaling (Li et al., 2007; 
Pedersen and David 2008). This is consistent with the high immunogenicity of rAdNS3, 
and the high antibody induction which resulted from the activation of B-cells induced by 
mir-181. mir-181 and mir-21 play a role in the regulation of inflammatory cytokine 
production (Moschos et al., 2007). Thus, increasing these miRNAs in immunized animals 
indicated that cytokine induction by the Ad vector has a role in activation of the immune 
response. These results confirmed the efficiency of Ad vector for vaccination. 
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To our knowledge, this is the first study to monitor the change in miRNA levels 
after vaccination. This study demonstrated a relationship between vaccines and miRNA, 
suggesting that miRNAs are involved in the regulation of the immune response. Further 
investigation to understand this relationship will help in the design of an effective 
therapeutic vaccine against HCV.  
 
3.5-Conclusion 
 
In this chapter, a recombinant Ad expressing the HCV NS3 was constructed and 
evaluated for its efficiency in immune response induction. 
The data presented in this chapter can be summarized as follows: 
1- rAdNS3 induced high antibody levels 6 weeks after vaccination with a single 
dose. 
2- rAdNS3 was more efficient than the plasmid vaccine pCNS3. 
3- The immune response induced by rAdNS3 correlated with upregulated miRNAs 
levels, specifically mir-181 and mir-21, which possibly enhance the immune 
response through the maturation of B and T cells. 
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CHAPTER 4 
ADENOVIRUS MEDIATED-RNA INTERFERENCE AGAINST NS3 
REGION OF HEPATITIS C VIRUS  
 
4.1- Introduction 
HCV is a global health burden, and it appears to be the main reason for liver 
transplantation and liver-related mortality. The current standard therapy is a combination 
of pegylated IFN-α and the nucleotide analogue ribavirin, which induces a sustained 
virologic response (SVR) in 50% of patients, depending on the virus genotype (Munir et 
al., 2010; Tsubota et al., 2011). Other factors, such as viral load and the age of the 
patient, also affect the outcome of the therapy (Foster, 2004; Feld and Hoofnagle, 2005). 
In addition, IFN/ribavirin is a long-term therapy and causes severe side effects. 
Therefore, new approaches are now being developed. Recently, RNAi technology 
attracted attention as a promising antiviral therapy that can suppress viral enzymes 
involved in replication. RNAi is a process of post-transcriptional gene silencing by a 
dsRNA of homologous sequence. Long dsRNAs are cleaved by Dicer, an RNase III-like 
enzyme, into 21-28 bp duplex siRNA (Bernstein et al., 2001; Paddison et al., 2002). 
siRNAs are then incorporated into RISC; the latter guides siRNA to the complementary 
mRNA, thus leading to the target mRNA cleavage and subsequent degradation with 
RNase H (Hammond et al., 2000; Gregory et al., 2005; Liu et al., 2004).  Alternatively, 
partial complementarity with the target mRNA would lead to inhibition of protein 
translation due to steric hindrance (Bartel, 2004, Meister et al., 2004). The main factors 
influencing successful RNAi therapy include target specificity and the effectiveness of 
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the delivery method. Conserved regions of the virus, particularly with a high mutation-
prone virus like HCV, should be targeted, provided that they are crucial for viral 
replication. The non-structural proteins perform vital processes required for viral 
replication. The main functional proteins are the protease and helicase encoded by NS3, 
and RdRP encoded by NS5B, therefore they are good target candidates for the siRNA, 
new therapeutic approaches. 
RNAi has been used for inhibiting several viruses, including HIV (Jacque et al., 
2002), poliovirus (Saleh et al., 2004), and HCV (Wilson et al., 2003; Randall et al., 
2003).  Different target regions in the mRNA as well as different siRNA delivery 
methods were used.  RNAi can be induced using siRNA duplex which binds directly to 
RISC or as shRNA expressed by a plasmid vector, and processed similarly to internal 
miRNA. The main hurdle to siRNA treatment remains the inefficient transfection 
method. The low cell transfection efficiency and the susceptibility of small RNAs to 
degradation by cellular RNases led to the search for an alternative approach. Different 
transfection methods were used, such as lipofictamine 2000 or electroporation (Wilson et 
al., 2003; Randall et al., 2003), however these methods have cytotoxic effects on the 
cells. Therefore shRNA vectors are preferable methods of delivery. Plasmids expressing 
shRNAs encoded by plasmid DNA or recombinant lentivirus vector effectively inhibited 
HCV replication in HCV subgenomic cell lines (Takigawa et al., 2004; Eisa et al., 2010). 
However, plasmid uptake is not effective in humans, resulting in a short duration of gene 
silencing. Therefore, viral vectors would be more effective.  In this study, the use of Ad 
vector was used to overcome the reported drawback of other delivery methods of siRNA 
against HCV.  Ad was used extensively in transgene expression, due to a number of 
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advantages including easy manipulation and high titer production. In addition, its wide 
tropism allows for efficient infection of a variety of cells, including liver cells. 
Adenovirus also elicits long-lived transgene expression that induces a durable effect. 
shRNA expressing Ad vectors were used successfully for silencing hepatitis B virus 
(HBV) (Carmona et al., 2006; Uprichard et al., 2005) and HCV (Sakamooto et al., 2008). 
Ad has been also used indirectly against HCV by silencing cellular cofactors that support 
HCV replication (Zhang et al., 2004). In this study, recombinant Ad vectors expressing 
shRNAs (rAd-shRNAs) against the HCV-NS3 region were constructed. Two different 
target sites were chosen: one in the protease and one in the helicase encoding sequences. 
In addition, two different promoters were used, U6 promoter and CMV ie promoter. NS3 
gene silencing by rAd-shRNAs was evaluated in Con1/FL-Neo cells. 
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4.2- Methods 
 
4.2.1- shRNA plasmid construction 
4.2.1.1- shRNA sequence synthesis 
The shRNA sequence was generated as two complementary oligonucleotides 
(ODN) (Sigma). Each strand consisted of two complementary sequences separated by a 
loop. The two strands were annealed and ligated to a shuttle plasmid. Two shRNA 
sequences were synthesized targeting the NS3 region. The siRNA target sequences were 
chosen using Ambion’s siRNA design tools. The NS3Si-Pro sequence targeted the 
CCAGGACCUCGUCGGCUGG site, located at 3656-3674 bps of the HCV-1b genome in 
the protease encoding part of NS3. SacI and EcoRI sites were added to the 5’ and 3’ end 
of each strand respectively, for cloning in the plasmid pDCG under control of CMV ie 
promoter. SacI lies in the last part of CMV ie promoter in pDCG plasmid, So this 
sequence was added to the shRNA oligo to complete the promoter. SacI was used to 
remove extra sequence between the promoter and the ShRNA. Also poly A signal 
AATAAA was added at the end of ShRNA sequence (Song et al., 2004). The AvrII site 
was added to the 5’ end for screening. NS3Si-Hel targeted the 
CUAGCGGAGACGUCAUUGU site located at 4624– 4642 bps of the HCV genome in 
the helicase encoding part of NS3. The two strands were synthesized to have EcoRI and 
PstI sites on both ends for cloning under the U6 promoter in the pDU6 plasmid. The KpnI 
restriction site was added for screening. To synthesize each shRNA, the two ODNs were 
mixed in an equal molar ratio in 20 μL nuclease free water and annealed using the 
iCycler PCR machine (Bio-Rad). The ODN mixture was heated to 94° C, followed by 
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lowering the temperature in decrements of 0.5° C every 10 sec. When the temperature 
reached 18° C, the mixture was cooled to 4° C. The ODNs used are listed in Table 4.1. 
Table 4.1: Oligonucleotides used to generate shRNA against NS3. 
shRNA Oligo Sequence 
shRNA-
NS3 
protease 
FwNS3si-1b 5’CGTTTAGTGAACCGTGGTACCCCAGGACCTCGTCGGCTGGTTCAAGAGACCAGCCGACGAGGTCCTGGAATAAACCTAGG 3’ 
RvNS3si-1b 5’AATTCCTAGGTTTATTCCAGGACCTCGTCGGCTGGTCTCTTGAACCAGCCGACGAGGTCCTGGGGTACCACGGTTCACTAAACGAGCT 3’ 
shRNA-
NS3 
helicase 
FwNS31b-
siU6 
5’AATTCTAGCGGAGACGTCATTGTTTCAAGAGAACAATGACGTCTCCGCT
AGTTTTTTGGTACCTGCA 3’ 
RvNS31b-
siU6 
5’GGTACCAAAAAACTAGCGGAGACGTCATTGTTCTCTTGAAACAATGACG
TCTCCGCTAG 3’ 
 
4.2.1.2- shRNA cloning  
Plasmids pDCG containing CMV ie promoter and pU6 containing U6 promoters 
were used to clone the shRNA ODNs resulting in two plasmids, pNS3-Si-Pro and pNS3-
Si-Hel respectively. The pDCG plasmid was digested with SacI and MfeI which is 
compatible with EcoRI in shRNA ODN, So EcoRi can be used for screening for the right 
plasmid. pU6 was digested with EcoRI and PstI (NEB).Approximately 0.5-5 µg DNA 
was digested with 1-10 units of the restriction enzyme, and incubated at 37º C for 2-3 h. 
Equal amounts of the two restriction enzymes were used with the appropriate buffer 
recommended by the manufacturer for the combination of these enzymes. The enzymes 
were then inactivated prior to ligation by heating to 70○ C for 20 min. Plasmid and 
shRNA fragments were ligated at a ratio of 1:3 using 400 units of bacteriophage T4 
ligase (NEB) in a 20 μL reaction. The reaction was incubated at room temperature for     
2 h. The plasmid was transformed in 100 µL of competent E. coli according to standard 
protocol (Sambrook et al., 1989). The transformed cells were spread on a selective agar 
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plate with ampicillin, and incubated at 37º C for 16 h. A few colonies were picked and 
cultured overnight at 37º C. The plasmids were isolated and screened via restriction 
enzyme digestion.  
 
4.2.1.3- Plasmid DNA isolation  
Small-scale plasmid DNA isolation was carried out with the Plasmid MiniPrep 
DNA Kit (Norgen Biotek Corp., ON) according to the manufacturer’s instructions. Prior 
to plasmid transfection, all plasmids were prepared in large scale, and purified with the 
Endotoxin Free Plasmid DNA MaxiPrep Kit (Norgen Biotek Corp.) according to the 
manufacturer’s instructions. 
 
4.2.1.4- Plasmid confirmation by sequencing 
The plasmids were sequenced to confirm the presence of shRNA, and to ensure 
mutations did not take place. DNA sequencing was performed at York University Core 
Molecular Biology and DNA Sequencing Facility. Cycle sequencing reactions were 
carried out with Bigdye Terminator chemistry on the Applied Biosystems 337 DNA 
Sequencer, using the appropriate primers. 
 
4.2.2- Adenovirus culture 
4.2.2.1- Adenoviral vector construction 
Recombinant adenovirus vectors encoding shRNAs were constructed by 
homologous recombination based on the AdMax (Microbix) adenoviral vector system as 
previously shown in Chapter 3. The shuttle plasmid (pNS3si-Pro or pNS3si-Hel) and the 
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adenovirus genomic plasmid pBHGfrtΔE1E3FLP were co-transfected into 293 cells, 
which produce the E1 protein necessary for viral packaging. The co-transfection was 
carried out in a 6-well plate. For each well, a transfection mixture, containing 5 µL 
lipofectamine 2000 (Invitrogen) and 2.5 µg from each plasmid in 500 µL Opti-MEM 
medium (Invitrogen), was used. Complete CPE was observed after 10 days. The medium 
and infected cells were harvested. To confirm the virus, the cells were lysed to extract 
viral DNA using a modification of the Hirt extraction method (Hirt, 1967).  Briefly, 
500μL of lysis solution (10 mM Tris-HCl, 100 mM EDTA, 0.4% (w/v) SDS, 0.5 mg/mL 
pronase) was added to the attached cells and the plate was then incubated at 37° C for 4-
10 h. The lysate was then loaded on a Norgen DNA isolation column to isolate the viral 
DNA.  Confirmation of the viral DNA was done by restriction enzyme digestion with 
HindIII. Finally the rAd-shRNA vectors were grown, purified on CsCl gradient and 
titrated using plaque assay.  
 
4.2.2.2- Titration of rAd-shRNA by plaque assay 
The plaque assay was performed to quantify the infectious particles of the virus. 
Briefly, 10-fold dilutions of the virus were prepared in 1 mL PBS++. In a 6-well plate, 
80-90% confluent 293 cells were infected with 1 mL of each dilution. After 1 h 
incubation at 37º C, the cells in each well were covered with a 6 mL mixture of equal 
volumes of 1% melted agarose solution with 2X MEM medium, at 44○C. The cells were 
incubated again at 37º C, 5% CO2 after the agarose layer solidified. The plaques were 
counted 5-7 d post-infection. The virus concentration was determined in PFU/mL as 
follows: titer = (number of plaques) (dilution factor)/(infection volume). 
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4.2.2.3- Adenovirus infection 
Con1/FL-Neo cells were infected with MOI 5 of rAd-shRNA targeting NS3. The 
Ad infection of mammalian cells was carried out in 6-well plates. The virus was mixed 
with PBS++ in a total volume of 500 µL/ well and then added to the cell monolayer (after 
aspirating the medium). The 6-well plate was then incubated for 1 h at 37º C with 96% 
relative humidity and 5% CO2 with swirling the plate every 15 min. After that, 2 mL of 
the culture medium was added to each well, and the plate was incubated for 48 h or as 
needed for the experiment. 
 
4.2.3- Quantification of NS3 inhibition 
4.2.3.1- RNA isolation 
Total RNA was isolated from FL-Neo con1 cells after transfection with Ad- 
shRNA. RNA isolation was performed using the Total RNA Purification Kit (Norgen 
Biotek Corp.) according to the manufacturer’s instructions. RNA integrity was assessed 
by electrophoresis on a formaldehyde agarose gel (Sambrook et al. (1989). The gel was 
viewed and photographed under UV light using the AlphaImager 2200 (Alpha Innotech). 
RNA was quantified by spectrophotometry (Sambrook et al., 1989). To inhibit the 
interference of cellular DNA, 50 µL of the RNA sample was digested with 4 units of 
TURBO DNaseI (Ambion) in a 100 µL reaction mixture, and incubated at 37° C for 30 
min, followed by purification using the CleanUp and Concentration Kit (Norgen Biotek 
Corp.), according to the manufacturer’s instructions. 
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4.2.3.2- Reverse transcription 
Two hundred nanograms of total RNA was used in RT reactions. RNA was 
combined with 0.5 µL of NS3-specific RT primer (50 mM stock) and completed to 5 µL 
final volume with RNase/DNase-free water (Ambion). This mixture was incubated for 5 
min at 70° C, and then cooled at 4° C. Fifteen microliters of the RT reaction solution was 
added to the mixture. The RT reaction solution contained 4 μL of 5X First Strand Buffer 
(250 mM Tris-HCl pH 8.3, 375 mM KCl and 15 mM MgCl2), 2 μL of 0.1 M 
Dithiothreitol (DTT), 1 μL of 10 mM dNTPs, 0.1 μL Superscript III reverse transcriptase 
(Invitrogen) and 7.9 μL RNase/DNase-free water. The reaction was incubated at 25° C 
for 5 min, followed by 90 min at 50° C. The reaction was inactivated by heating at 70° C 
for 15 min and held at 4° C.    
 
4.2.3.3- Quantitative PCR 
The level of NS3 cDNA was quantified by qPCR. The reaction was performed 
using the Bio-Rad iCycler thermal cycler. In a 20 μL reaction, 10 µL of 2 X SYBR® 
Green PCR Mastermix (BioRad) was mixed with 1 µL of each primer (5mM stock) and 4 
µL of cDNA template. The reaction began with 15 min at 95○ C followed by 40 cycles of 
three steps: 95○ C for 15 sec, 60○ C for 30 sec and 72○ C for 30 sec. The reaction was 
incubated for 1 min at 57○ C before starting a melting curve analysis by a 0.5° C 
increment decrease every 10 sec over 80 rounds. To determine the initial concentration of 
NS3 cDNA, the CT values of NS3 were normalized to the house keeping gene S15. The 
results were calculated with the ∆∆CT method and are indicated as a change in fold 
compared to the NS3 cDNA levels from non-infected cells. 
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4.3- Results 
4.3.1- Confirmation of the pNS3-Si-Pro plasmid 
pNS3-Si-Pro construction and screening is illustrated in Figure 4.1 and 4.2. The 
plasmid was confirmed with NcoI and AvrII enzyme digestion and yielded two expected 
bands, 3638 and 283 bp. The extra band of 2000 bp is possibly due to non-digested 
plasmid. The plasmid was also confirmed by sequencing. 
 
 
  
 
 
 
Figure 4.1: Schematic diagram of the construction of the shRNA plasmid against the protease 
(pNS3-Si-Pro). 
 
 
 
 
 
 
 
 
Figure 4.2: Confirmation of pNS3-Si-Pro by restriction digestion. Plasmid DNA was digested 
with NcoI and AvrII. The resultant bands were the expected size 3638 and 283 bps. L: Norgen’s 
FullRanger ladder. The size of Ladder bands is shown in bp. 
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4.3.2- Cconfirmation of the pNS3-Si-Hel plasmid 
  pNS3-Si-Hel construction and confirmation is illustrated in Figure 4.3 and 4.4. 
The plasmid was confirmed with KpnI restriction enzyme digestion and yielded two 
expected bands, 4596 and 757 bp. The plasmid was also confirmed by sequencing. 
. 
 
 
 
 
 
 
 
Figure 4.3: Schematic diagram of the construction of shRNA plasmid against helicase (pNS3-Si-
Hel). 
 
 
 
 
 
 
 
 
Figure 4.4: Confirmation of  pNS3-Si-Hel by restriction enzyme digestion. Plasmid DNA was 
digested with KpnI. The resultant bands were the expected sizes, 4596 and 757 bps.   L: Norgen’s 
MidRanger ladder. The size of ladder bands is shown in bp. 
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4.3.3- Confirmation of rAd-shRNAs against NS3 
Ad vectors encoding shRNA sequences targeted to HCV RNA were rescued by 
homologous recombination between the shuttle vectors constructed previously (pNS3-Si-
Pro or pNS3-Si-Hel) and the Ad plasmid pBHGfrtdel13FLP in 293 cells. The 
construction strategy is shown in Figures 4.5 and 4.6. 
 The recombinant viral vectors, rAdsiNS3-Pro and rAdsiNS3-Hel, were 
confirmed by HindIII digestion as shown in Figure 4.7. The digestion bands shown are 
similar to the expected bands from the restriction analysis of the Ad vectors, compared to 
the wild type virus (Ad5) shown inTable 4.2. 
We further confirmed the absence of any wild type virus (Ad5) contamination due 
to homologous recombination with the Ad E1 gene in 293 cells. PCR was performed on 
the viral DNA isolated from 293 cells infected with the adenoviral vectors rAdNS3-Si-
Pro and rAdNS3-Si-Hel using the AdE1 primer. The PCR results showed no 
amplification in either viral DNA, confirming that the viruses are resultant only from 
homologous recombination between the adenovirus plasmid and the shRNA transcription 
cassette. Plasmid encoding AdE1 (pE1) was used as a positive control template to 
confirm that PCR reaction worked. The PCR results are shown in Figure 4.8. 
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Figure 4.5: Schematic diagram representing the construction of the recombinant 
adenovirus (rAdNS3-Si-Pro) through a homologous recombination system in HEK 293 
cells. 
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Figure 4.6: Schematic diagram representing the construction of the recombinant 
adenovirus (rAdNS3-Si-Hel) through a homologous recombination system in HEK 293 
cells. 
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Table 4.2: Restriction enzyme analysis of Ad-shRNAs against NS3 and Ad5. The 
fragment sizes underlined indicate the bands that are different from Ad5 and specific to 
rAd-shRNAs. 
HindIII digestion Wild type Ad5 rAdNS3-Si-Pro rAdNS3-Si-Hel 
Fragments (bp) 
8010 
5665 
5324 
4597 
3437 
2937 
2804 
2081 
1008 
75 
8010 
5322 
4597 
3894 
3012 
2937 
2081 
1004 
75 
8010 
5328 
5322 
4597 
3012 
2937 
2081 
1004 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Confirmation of rAd-shRNA vectors. The agarose gels show the rAdNS3-Si-Pro (A) 
and rAdNS3-Si-Hel (B) digested with HindIII. The bands were as expected as shown in the table 
5.1. L:  Norgen’s UltraRanger ladder. The sizes of ladder bands are shown in bp. 
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Figure 4.8: PCR amplification of AdE1 from rAdNS3-Si-Pro (lane 1) and rAdNS3-Si-Hel (lane 
2). The plasmid encoding E1 (pE1) was used as the +ve control (479 bp band of E1 was 
obtained). E1 showed no amplification with either Ad vectors. Control: no template.  L: Norgen 
FastRunner marker. The sizes of the ladder bands are shown in bp. 
 
4.3.4- Down regulation of NS3 with recombinant rAd-shRNAs 
 The silencing activity of the rAd-shRNAs against the HCV-NS3 gene was 
evaluated in Con1/Fl-Neo cells, containing the HCV RNA replicon. The cells were 
infected with the rAdNS3-Si-Pro targeting protease and rAdNS3-Si-Hel targeting 
helicase at an MOI of 5. The level of NS3 mRNA was quantified at 48 h post-infection 
by qRT-PCR. The results showed siRNA against protease was more effective. It 
suppressed the expression of NS3 by 90%. The reduction in NS3 expression was 
statistically significant (p < 0.05). However, siRNA against helicase resulted in a non 
statistically significant level (p > 0.05). The results are shown in Figure 4.9. 
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Figure 4.9: The effect of shRNA on the mRNA level of NS3 after infection of Con/FL-
Neo cells with rAdNS3-Si-Hel and rAdNS3-Si-Pro. The NS3 level was expressed as a 
change in fold of NS3 expression compared to the control cells (not infected) measured 
by ΔΔCt method. Results were normalised against the S15 gene. Error bars represent the 
standard deviations, (n=3). Results are considered significant (*) if p value < 0.05 as 
shown by T-test.  
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4.4- Discussion 
 
RNAi activity against viruses showed promising results suggesting a potential 
application of siRNA in antiviral therapy. HCV replication and persistence in the cell was 
found to be dependent on critical viral proteins, such as helicase and protease, encoded by 
NS3, and polymerase, encoded by NS5B (Suzuki, 2007).  In this study, NS3 was used as 
a target for siRNA, due to its highly conserved sequence among the sub genotypes. That 
ensures the perfect complementation required for efficient cleavage. Although the 5’UTR 
region is the most conserved part of the HCV genome, and it contains the IRES 
responsible for initiating cap-independent translation of the virus, the secondary 
structures and the multiple sites involved in RNA–protein interaction within the 5’UTR 
may protect the target sequence from recognition by siRNA. Thus, NS3 seems to be an 
ideal target and more effective in inhibiting the replication of HCV. shRNA expressing 
plasmids against NS3 showed inhibition of the expression and viral replication (Eisa, 
2010; Takigawa et al., 2004). Other targets such as the core, 5’UTR, NS5b was also 
tested using shRNAs expressed by plasmids or lentivirus vectors. These results showed 
that NS3 and NS5b were more effective Targets. In addition the lentivirus induced 
prolonged effect compared to the plasmid (Takigawa et al., 2004). 
In the current study, two shRNAs sequences targeting the NS3 region were tested. 
Ad vectors were used for efficient siRNA delivery. NS3 encodes two essential enzymes 
for viral replication, protease and helicase. Two rAd-shRNAs against both the protease 
and helicase were constructed and tested on Con1/FL-Neo cells. The results showed that 
the shRNA sequence expressed by rAdNS3-Si-Pro was capable of significantly inhibiting 
the expression of NS3 (to 90% less than non-infected cells) (Figure 4.9). This high 
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inhibition may be due to the degradation of HCV genomic RNA as the siRNA sequence 
was designed with 100% homology to the target site. This would also indicate the 
integrity and absence of mutations in the target site. Ad virus showed high inhibition of 
NS3, which agreed with Sakamoto et al., (2008) who evaluated Ad vector mediated 
shRNA against different target (5’UTR). siRNA against protease transcribed by the CMV 
ie promoter showed high activity similar to that obtained by Takigawa et al. (2004), who 
used a similar sequence under the control of the U6 promoter. The U6 promoter is 
responsible for the transcription of short RNA by polymerase III, and it is commonly 
used for shRNA transcription cassette construction. The results indicated that the CMV ie 
promoter can optimally transcribe shRNAs. This would be useful for delivery of antigens 
and shRNA sequences in only one transcription cassette. 
rAdNS3-Si-Hel displayed little inhibition with no statistical significance, possibly 
due to a point mutation or secondary structure at the target site which hampered the 
access of the siRNA strand (Eisa, 2010). In addition, it was observed that siRNA target 
sequences are not all effective in gene silencing, and thus several sequences have to be 
tested to reach the optimal targets (Reynolds et al., 2004). The siRNA against helicase 
was transcribed by U6. Since U6 is an ideal promoter for short RNA transcription, the 
low activity is clearly due to the shRNA sequence itself, and not the promoter. 
Regardless, testing several siRNAs and targeting more than one sequence in the same 
gene may be beneficial in gene suppression and control of escape mutants.  
Finally, this study provides a proof of principle for using Ad vectors as an 
effective siRNA delivery strategy to suppress HCV proliferation, regarding siRNA 
stability, cellular uptake and cellular targeting due to their broad tropism. The strong 
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suppression effect of rAd-shRNA against the protease, suggests that this strategy may be 
effective in inhibiting viral proliferation in vivo since protease is a key factor in 
polyprotein processing and viral replication. Additionally, it would be beneficial to use 
several shRNAs targeting different regions of the HCV genome to further enhance the 
inhibitory activity. 
 
4.5. Conclusion 
The conclusion from this chapter is as follows: 
1- Two Ad vectors carrying shRNA against HCV-NS3 were constructed, one is 
directed against the protease (rAdNS3-Si-Pro) and the other against the 
helicase (rAdNS3-Si-Hel). 
2- rAdNS3-Si-Pro induced aproximately 90% reduction in the level of NS3 
mRNA. 
3- rAdNS3-Si-Hel induced only a non-significant reduction in NS3 mRNA. 
4- Not all siRNAs are optimal for supressing gene expression. 
5- The CMV ie promoter displayed optimal activity that is comparable to the U6 
promoter in transcription of shRNAs. 
6- Ad vectors were shown to be promising candidate for efficient shRNA 
delivery. 
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GENERAL CONCLUSION 
 
In this thesis, three approaches for vaccination and therapy against HCV were 
investigated. These include using alternative promoters and viral delivery aiming to 
optimize HCV vaccine efficacy as well as using siRNA to control the virus replication as 
a therapeutic approach.   
In the first strategy, the effect of various promoters on the efficacy of DNA 
vaccines was evaluated, more specifically, the weak but immediate early promoter E1A, 
the strong but late promoter MLP. These promoters were compared to the standard CMV 
ie promoter.  In the animal model tested, the CMV ie promoter appears to be more 
effective than the other promoters tested.   
In the second strategy, an adenovirus vector expressing the HCV-NS3 gene was 
constructed.  The data demonstrated a high antibody titer level upon injection of the mice 
due to the efficient gene delivery and high levels of gene expression. A durable immune 
response was observed six weeks after single dose administration. Moreover, miRNAs, 
indicative of a strong immune response, were detected. mir-181 and mir-21 were up-
regulated after immunization with the Ad vector, indicating a correlation between the 
miRNA level and the immune response elicited by Ad.  
In the third strategy, siRNAs against the HCV protease and helicase were 
expressed by Ad vectors. The data indicated that the siRNA sequence against protease 
could successfully target the mRNA of NS3 for inhibition, indicating that RNAi would be 
an effective antiviral therapy. In addition, target choice and delivery method are critical 
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for effective RNAi therapy. Ad vectors have been shown to be a potent delivery method 
for siRNA.   
In summary, the results showed that promoter strength and delivery method have 
an important impact on vaccine outcome. Moreover, siRNA can effectively inhibit gene 
expression of HCV. The Ad vaccine encoding NS3 and E1 is a candidate vaccine, 
capable of inducing a high and durable cross reactive immune response. However, small 
animal models are not ideal for evaluation of DNA vaccines. Therefore, testing in a large 
animal model is necessary. Also, Ad-encoding shRNA against protease could be a 
successful therapeutic approach to clear the HCV infection. The elevated level of 
miRNAs after vaccination,, indicates their role in immune response regulation. This 
suggests that miRNAs could be novel regulators to enhance vaccine efficacy as well as 
measuring tools to evaluate the immune response induced by vaccines.  
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    1 tatgaagtgc gcaacgtatc cggagtgtac catgtcacga acgactgctc caacgcaagc 
   61 attgtgtatg aggcagcgga catgatcatg catacccccg ggtgcgtgcc ctgcgttcgg 
  121 gagaacaact cctcccgctg ctgggtagcg ctcactccca cgctcgcggc caggaacgct 
  181 agcgtcccca ctacgacgat acgacgccat gtcgatttgc tcgttggggc ggctgctctc 
  241 tgctccgcta tgtacgtggg agatctctgc ggatctgttt tcctcgtcgc ccagctgttc 
  301 accttctcgc ctcgccggca cgagacagta caggactgca attgctcaat atatcccggc 
  361 cacgtgacag gtcaccgtat ggcttgggat atgatgatga actggtcacc tacagcagcc 
  421 ctagtggtat cgcagttact ccggatc  
 
 
Figure A.1: The sequence of HCV-E1 cDNA (truncated) (447 bp).  
                                                                        
    1 gcgcctatta cggcctactc ccaacagacg cgaggcctac ttggctgcat catcactagc 
   61 ctcacaggcc gggacaggaa ccaggtcgag ggggaggtcc aagtggtctc caccgcaaca 
  121 caatctttcc tggcgacctg cgtcaatggc gtgtgttgga ctgtctatca tggtgccggc 
  181 tcaaagaccc ttgccggccc aaagggccca atcacccaaa tgtacaccaa tgtggaccag 
  241 gacctcgtcg gctggcaagc gccccccggg gcgcgttcct tgacaccatg cacctgcggc 
  301 agctcggacc tttacttggt cacgaggcat gccgatgtca ttccggtgcg ccggcggggc 
  361 gacagcaggg ggagcctact ctcccccagg cccgtctcct acttgaaggg ctcttcgggc 
  421 ggtccactgc tctgcccctc ggggcacgct gtgggcatct ttcgggctgc cgtgtgcacc 
  481 cgaggggttg cgaaggcggt ggactttgta cccgtcgagt ctatggaaac cactatgcgg 
  541 tccccggtct tcacggacaa ctcgtcccct ccggccgtac cgcagacatt ccaggtggcc 
  601 catctacacg cccctactgg tagcggcaag agcactaagg tgccggctgc gtatgcagcc 
  661 caagggtata aggtgcttgt cctgaacccg tccgtcgccg ccaccctagg tttcggggcg 
  721 tatatgtcta aggcacatgg tatcgaccct aacatcagaa ccggggtaag gaccatcacc 
  781 acgggtgccc ccatcacgta ctccacctat ggcaagtttc ttgccgacgg tggttgctct 
  841 gggggcgcct atgacatcat aatatgtgat gagtgccact caactgactc gaccactatc 
  901 ctgggcatcg gcacagtcct ggaccaagcg gagacggctg gagcgcgact cgtcgtgctc 
  961 gccaccgcta cgcctccggg atcggtcacc gtgccacatc caaacatcga ggaggtggct 
 1021 ctgtccagca ctggagaaat ccccttttat ggcaaagcca tccccatcga gaccatcaag 
 1081 ggggggaggc acctcatttt ctgccattcc aagaagaaat gtgatgagct cgccgcgaag 
 1141 ctgtccggcc tcggactcaa tgctgtagca tattaccggg gccttgatgt atccgtcata 
 1201 ccaactagcg gagacgtcat tgtcgtagca acggacgctc taatgacggg ctttaccggc 
 1261 gatttcgact cagtgatcga ctgcaataca tgtgtcaccc agacagtcga cttcagcctg 
 1321 gacccgacct tcaccattga gacgacgacc gtgccacaag acgcggtgtc acgctcgcag 
 1381 cggcgaggca ggactggtag gggcaggatg ggcatttaca ggtttgtgac tccaggagaa 
 1441 cggccctcgg gcatgttcga ttcctcggtt ctgtgcgagt gctatgacgc gggctgtgct 
 1501 tggtacgagc tcacgcccgc cgagacctca gttaggttgc gggcttacct aaacacacca 
 1561 gggttgcccg tctgccagga ccatctggag ttctgggaga gcgtctttac aggcctcacc 
 1621 cacatagacg cccatttctt gtcccagact aagcaggcag gagacaactt cccctacctg 
 1681 gtagcatacc aggctacggt gtgcgccagg gctcaggctc cacctccatc gtgggaccaa 
 1741 atgtggaagt gtctcatacg gctaaagcct acgctgcacg ggccaacgcc cctgctgtat 
 1801 aggctgggag ccgttcaaaa cgaggttact accacacacc ccataaccaa atacatcatg 
 1861 gcatgcatgt cggctgacct ggaggtcgtc acg 
 
Figure A.2: The sequence of HCV-NS3 cDNA (1893 bp).  
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